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OBJECTIVE: Compare long-term mortality of patients after mechanical versus         
bioprosthetic aortic valve replacement in Newfoundland and Labrador 
 
METHODS: Retrospective cohort analysis of patients aged 50 to 70 years who            
underwent aortic valve replacement in Newfoundland and Labrador between 2006 and           
2014. A logistic regression propensity score generated a subset of 52 matched patients.             
The long-term outcome of survival was assessed. 
 
RESULTS: Of 189 patients included, 135 (71%) received mechanical valves, while 54            
(29%) received bioprosthetic valves. The mean age in the matched group was 63             
(mechanical) and 64 years (bioprosthetic) (P = 0.64). Mean follow-up was 8.1 (maximum             
13.8) years. Survival at 30 days, 1, 5, and 10 years was: 100%, 96%, 85%, and 81%                 
(mechanical) versus 100%, 96%, 89%, and 67% (bioprosthetic). The hazard ratio for            
mortality between mechanical and bioprosthetic valves was 0.64 (95% CI 0.18-2.3, P =             
0.491). Secondary outcomes revealed that the most common cause of death to be             
cardiovascular in etiology (39%), followed by malignancies (27%). 
 
CONCLUSIONS: We found no statistically significant difference in long-term survival          






The aortic valve is one of four valves in the heart and is subject to several diseases                 
that can significantly impact one’s life, including causing death. The most common of             
these diseases of the aortic valve is aortic stenosis - where the valve becomes partially               
blocked. To address this, surgeons can remove a patient's valve and replace it with a new                
one in a procedure called aortic valve replacement. There are two general types of valves               
that surgeons can use: mechanical and bioprosthetic valves. We set out to determine             
which valve type was associated with longer survival after aortic valve replacement. We             
included patients from Newfoundland and Labrador, and those who were between 50 and             
70 years of age. We found that there was no statistically significant difference in              
long-term survival between mechanical and bioprosthetic aortic valve replacement. We          
also highlighted a potential increase in congenital heart disease as a cause for aortic valve               
disease in NL. The most common cause of death was cardiovascular. These results agree              
with other published studies and are beneficial in the planning and delivery of future              
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Chapter 1: Background 
 
1.1 Aortic Valve Pathologies 
 
The aortic valve is one of four valves in the normal human heart and divides the                
heart from the rest of the body. As such it is the last structure that blood travels through                  
before leaving the heart. Its function is to ensure antegrade flow of blood away from the                
left ventricle towards the systemic circulatory system. It normally has three cusps that             
open and close in unison in response to changes in blood pressure in the left ventricular                
outflow tract and the aorta. The aortic valve is subject to a number of pathologies, this                
most common etiologies being: aortic stenosis (AS), aortic regurgitation (AR), and           
infective endocarditis (IE) [1]. Importantly, these pathologies often co-exist and may           
result in significant morbidity and mortality for patients. 
 
Among adults, there are three principle etiologies of AS: degenerative          
calcification of a normal trileaflet valve, calcification of a congenitally bicuspid or            
unicuspid aortic valve, and rheumatic aortic valve disease [1, 2]. Although rheumatic            
aortic valve disease is often considered the most common cause of AS worldwide, it is               
uncommon in North America and Europe [2]. Aortic valve disease in North America and              
Europe is most commonly due to calcification of a native trileaflet valve or congenitally              
bicuspid valve. The prevalence of AS increases with age [3]. The prevalence among             
adults aged 70 to 79 years is approximately 3.9 percent, and becomes 9.8 percent at ages                
80 to 89 years. Bicuspid aortic valves are thought to be present in 1 to 2 percent of the                   
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population with men affected more commonly than women [1]. Patients with AS due to              
calcification of a bicuspid aortic valve tend to become symptomatic approximately one            
decade earlier than the degenerative type of AS. The natural history of AS involves a               
prolonged asymptomatic period. Adults tend to become symptomatic once the stenosis is            
considered severe as defined by an aortic valve area of less than or equal to 1.0                
centimeters squared, a jet velocity of 4 meters per second or more, and a mean               
transvalvular gradient of 40 or more millimeters of mercury (mmHg). The signs and             
symptoms of AS are non-specific and commonly include angina, syncope, heart failure,            
and atrial fibrillation (AF). Upon the onset of these symptoms there is a marked increase               
in mortality as shown in Figure 1.1. Sudden cardiac death has also been a recognized               
complication of AS and is of particular concern. Sudden death in patients with AS who               
are asymptomatic occurs at a rate of less than 1% per year [85]. The incidence of sudden                 
death among patients with symptomatic AS is markedly increased with some reports of a              
mortality of 26% at one year after symptom onset [86]. 
AR is usually the result of pathology of the aortic valve leaflets themselves (e.g.              
valvular AR) or secondary to dilatation of the aortic root around the aortic valve.. There               
are three principle etiologies of valvular AR: bicuspid aortic valve, IE, and rheumatic             
aortic valve disease [1, 4, 5]. AR as a result of aortic root dilatation occurs when the                 
aortic annulus dilates to the point that there is separation of the leaflets. AR can present                
as either an acute or chronic process and often results in heart failure, conferring              
significant morbidity and mortality. 
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Figure 1.1: The natural history of aortic stenosis [2] Copyright UpToDate 2020 - used              
with permission. 
 
Symptomatic AS and AR account for the most commonly diagnosed valvular           
heart diseases in adults and are associated with increased morbidity and mortality if they              
remain untreated [6]. There is a need to address these pathologies. Medical treatments             
exist for complications of AS and AR such as heart failure. However, surgical             
interventions are required to address the underlying pathologies and have become the            
standard of care for severe, symptomatic AS and AR [7]. Surgical aortic valve             
replacement (SAVR) significantly improves survival, symptoms, and quality of life [1-4]. 
 
It is expected that demand for aortic valve interventions will increase in the             
future. In a 2019 published randomized controlled trial, Duk-Hyun Kang et al.            
demonstrated that patients with asymptomatic severe AS who underwent aortic valve           
interventions had improved mortality outcomes when compared to usual care [8].           
Further, it has been noted that 30% to 40% of patients with severe AS or AR are deemed                  
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to be unsuitable for SAVR due to their comorbidities and high predicted surgical             
mortality [6, 9]. Many of these patients are considered elderly and frail [10]. As the               
interventions mature and operator-experience increases, it is expected that patients          
previously considered too high risk may become candidates for surgical intervention [11].            
These recent advancements suggest that aortic valve interventions may become more           
prevalent in the future with a broader set of patients becoming candidates for AVR. With               
the potential for increasing demand on aortic valve interventions, and their demonstrated            
benefit, there is a need for improved understanding of the relative benefits and             
disadvantages of the various aortic valve replacement (AVR) options available to           
patients. 
 
1.2 History of Aortic Valve Replacement 
 
1.2.1 Development of Mechanical Valves 
 
The development of prosthetic valves for human valve replacement began in the            
1950’s and culminated with the first successful AVR in 1960 by Dwight Harken [12].              
This initial valve employed a “double-caged ball” design and was implanted in five             
patients of which one patient survived the perioperative period leading the innovators of             
this intervention to conclude that aortic valve pathologies are “beyond surgical           
correction”. Despite the poor outcomes of this initial case series, interest in this procedure              
grew and a further 117 AVRs were performed between 1961 and 1964 [13]. The first               
study evaluating the characteristics and outcomes of a cohort of AVR patients was             
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published in 1965 [13]. This study commented that there were “uniformly unfavourable            
results” after aortic valve repair, and heralded the era of prosthetic AVR after outlining              
the superiority with a ball-valve prosthesis despite high operative mortality [14]. By the             
late 1960’s improved mechanical valve designs emerged using a tilting-disc prosthesis.           
The Björk-Shiley valve was designed with a central disk rotating on an axis and was the                
first valve of this design to be widely implanted [15]. Due to excessive             
thromboembolism, this design was eventually terminated [15]. These initial efforts to           
develop an effective aortic valve prosthesis identified five major problems with           
mechanical valves: hemodynamic performance, safety and durability, thromboembolism,        
prosthesis-induced hemolysis, and IE [16]. Nicoloff et al. recognized dissatisfaction with           
existing prostheses at that time and developed the bileaflet St. Jude Medical (SJM)             
prosthesis [16]. Nicoloff and his team implanted the first SJM prosthesis in October 1977              
and presented encouraging results in 1981 after completing 22 surgical AVR (SAVR)            
procedures [16]. The SJM prosthesis became the most widely used aortic valve prosthesis             
by the end of the 1980s [17].  
 
1.2.2 Development of Bioprosthetic Valves 
 
Interest in bioprosthetic designs existed after promising results in animal studies           
[18]. Donald Ross performed the first AVR using a bioprosthetic design in July 1962, and               
by 1969 he reviewed outcomes after his group inserted more than 350 such valves [18,               
19]. At these early stages the advantages of bioprosthetic valves were identified including             
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the ability to implant valves that more closely matched normal human aortic valve design              
and hemodynamics. Further benefits of bioprosthetic valves that Ross identified included           
a reduction in thromboembolic complications, hemolysis, and IE [19]. The disadvantages           
noted were of a more complicated surgical procedure, and valve failure and degeneration.             
These initial bioprosthetic valves used cadaveric homografts which were difficult to           
collect and preserve [14]. Subsequent generations of bioprosthetic valves used xenografts           
- valves collected from animals. The first successful AVR with a xenograft was carried              
out in September 1965 [20]. These xenografts were examined after the initial            
implantations and were found to suffer from degeneration and immunological          
incompatibility [21]. Efforts were made to develop methods of preparing porcine valves            
while preventing inflammatory reactions in the human body [22]. Carpentier introduced           
the use of glutaraldehyde to make the tissue immunologically inactive thus preserving the             
xenografts and improving their durability - a chemical still used today [21]. In 1971              
Marian Ionescu created and implanted an aortic valve using bovine pericardium attached            
to a support frame [23]. Production of this “Ionescu-Shiley Pericardial Xenograft” began            
in 1976 and has since undergone several modifications. As bioprosthetic valves gained            
wider use the issue of patient-prosthesis mismatch became clear [24]. It was recognized             
that there was a reduction in effective orifice size after SAVR with these first and second                
generation valve prostheses, which was associated with increased mortality and structural           
valve deterioration (SVD) [24]. 
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1.2.3 Beyond Mechanical and Bioprosthetic Valves 
 
Due to limitations with bioprosthetic and mechanical valves cardiothoracic         
surgeons explored innovative options to address aortic valve pathologies beyond          
implantation of an isolated aortic valve. A unique approach involved the creation of a              
new left ventricular outflow tract. This aorto-apical conduit was first implanted in            
humans in 1963 by Templeton [25]. After the initial success in the 1960’s this procedure               
became more widely adopted in the 1970s and 1980s and a high incidence of prosthesis               
dysfunction became clear leading to the procedure becoming mostly discontinued [26]. In            
1962 Donald Ross proposed the Ross Procedure whereby a pathological aortic valve is             
replaced with the patients pulmonary valve, and bioprosthetic pulmonary prosthesis was           
implanted [19]. He and Magdi Yacoub first carried out this procedure in 1967.             
Advantages of the procedure included a reduction in thromboembolism and the ability of             
the valve to grow with the patient; however, it addressed a single-valve pathology by              
disrupting two valves leading to increased long-term difficulties. This procedure has           
remained popular among children, but remains limited in use for adults [27]. Stentless             
valves were then introduced in 1988 [28] and became popular in the following decade              
due to their reduced size and improved hemodynamics [14]. These stentless valves were             
used in complete root replacement surgeries. Long-term studies of these stentless valves            
failed to find an improvement in survival and noted a significant increase in SVD after a                
medium period of time [29, 30]. Due to their smaller size, stentless valves allowed for the                
next generation of sutureless design which remain in trials today. 
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1.2.4 Minimally Invasive Approaches 
 
An alternative minimally-invasive approach to AVR was introduced in 1996 by           
Delos Cosgrove. This technique avoided the need for a full median sternotomy and             
central cardiopulmonary bypass and allowed for intervention in the more frail and elderly             
populations [10]. Current techniques for minimally invasive SAVR include upper          
hemi-sternotomy and right anterior thoracotomy that is video assisted. Improved          
catheter-based technology led to the advent of transcatheter aortic valve implantation           
(TAVI). The first such procedure was carried out in 2002 by Cribier and utilized a               
balloon-expandable stent with 3 bovine pericardial leaflets [31]. This successful          
percutaneously implanted aortic valve led to the further evolution of bioprosthetic valves            
and the development of various delivery designs. In 2005, Paniagua et al, reported the              
first TAVI implanted through a retrograde approach [32]. Following these two initial case             
reports Cribier et al. reported on 36 patients who were deemed to not be candidates for                
SAVR and underwent TAVI [33, 34]. They concluded that this intervention was feasible             
and led to hemodynamic and clinical improvement. TAVI has matured since these initial             
experiences and has transformed the management of severe aortic stenosis [11]. Several            
issues have been identified with the TAVI approach including vascular complications           
such as cerebrovascular accidents (CVAs), atrioventricular conduction block, and         
paravalvular leakage. A major advantage of TAVI is the opportunity to provide AVR for              
the 30-40% of patients with severe, symptomatic AS who otherwise are deemed            
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unsuitable for surgical interventions due to their comorbidities and high predicted           
surgical mortality [35]. The current generation of TAVI have resulted in significant            
improvements in the aforementioned issues, and this technique is becoming first line            
treatment for many patients with AS that require a bioprosthetic valve. 
 
1.2.5 The Influence of Valve-in-Valve Procedures 
 
As TAVI becomes mainstream for patients with AS, the question of durability            
remains. Younger patients, those less than 70 years of age, who have a TAVI are at risk                 
of the valve undergoing SVD. Therefore, they may require a sternotomy to allow for              
explant of the valve. However, more recently, TAVI provides an unconventional           
opportunity through “valve-in-valve” procedures to avoid the need for redo SAVR. The            
first such procedure was described by Peter Wenaweser in 2007 and demonstrated            
feasibility and success of the approach [36]. Several case series and registries of             
valve-in-valve procedures have since been published [37-40]. These valve-in-valve         
procedures address the major disadvantage of bioprosthetic SAVR by providing an           
opportunity to safely manage SVD. The advent of valve-in-valve TAVI has the            
opportunity to transform the indications of mechanical versus bioprosthetic SAVR -           
long-term results of valve-in-valve TAVI will eventually shed light on and influence            
future trends in AVR. However, there is anecdotal evidence that some surgeons are no              
longer implanting mechanical valves in younger patients given the presumed impact of            
life-long anticoagulation and the potential benefit of a TAVI valve-in-valve procedure. 
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This novel procedure is attractive as a less invasive option for patients; however,             
it is not without risk as it carries a high perioperative mortality [82, 83], among other                
safety concerns [84]. Due to the design and method of implantation there are risks of               
serious consequences such as obstruction of the coronary arteries, compression of the            
cardiac conduction system, malposition or migration of the valve, high post-procedural           
gradients across the new valve, and vascular complications at the access site (usually the              
femoral artery). Overall, there have been continuous advancements in the development of            
both mechanical, and bioprosthetic valves; and our understanding of their relative           
advantages and limitations. Nowadays, conventional, minimally invasive, and        
catheter-based approaches are performed internationally, with ever-improving clinical        
results. Consequently, AVR is the mainstay of treatment for severe AS and AR [41, 42].               
Conventional surgeries continue to be the gold-standard approach [43], whereas          
minimally invasive approaches are reserved for patients with high surgical risk. 
 
1.3 Relative Advantages and Disadvantages of Mechanical and        
Bioprosthetic Valves 
 
AVR remains the only effective treatment option for AS and AR. Despite            
significant technological advances over the decades, the procedure continues to be           
associated with significant risks of morbidity in patients who receive these operations.            
AVR is largely divided into two surgical options: mechanical and bioprosthetic           
prostheses. Recommendations for which valve design to use are based upon known            
differences in the natural history and associated complications of these valves. 
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The major risks associated with mechanical valves relate to the materials being            
used. The metallic components result in high shear stress on blood flow that damages              
cells and proteins in the blood. This can activate coagulation pathways and results in              
increased thromboembolic events [1]. Patients who receive mechanical valves require          
lifelong anticoagulation - usually with warfarin - which itself introduces morbidity [1, 41,             
42]. Although appropriate use of anticoagulation reduces the risk of thromboembolism, it            
can be difficult to maintain the international normalized ratio (INR) within the targeted             
2.0-3.0 for mechanical aortic valves [41]. The long-term use of anticoagulation           
introduces the risk of spontaneous and trauma-related bleeding and is a major contributor             
to morbidity and mortality after SAVR [88]. Reported rates of bleeding with warfarin             
depend on known risk factors for bleeding including age and comorbidities. Rates of             
bleeding in patients anticoagulated with warfarin for mechanical valves have been           
reported to be as high as 22.2% per patient-year [89]. The majority of these bleeding               
events are considered minor. In recent studies, the incidence of major bleeding events has              
varied from 0.34% to 1.4% per patient-year [89-92]. The major advantage of a             
mechanical valve is that SVD is rare, reducing the need for reoperation. There are              
non-structural causes of deterioration in mechanical valves including pannus growth,          




Bioprosthetic valves, on the other hand, are generally produced with bovine or            
equine pericardium or from porcine aortic valves. These bioprosthetic valves are           
associated with a higher risk of reoperation because of SVD from wear-and-tear [23, 24,              
45]. Well recognized risk factors for SVD include young patient age, renal failure,             
abnormal calcium metabolism, and patient-prosthesis mismatch [93, 94]. Accelerated         
SVD in younger patients are thought to be related to increased immunological response             
and calcification of the prosthetic valve as compared to elderly patients [46-48]. The             
average lifespan of a bioprosthetic AVR has been reported to range from 10 to 15 years                
[23, 24, 45] upon which there is a need for reoperation. Traditionally, reoperation             
involved a second sternotomy and exposed the patient to the associated morbidity and             
mortality. More recently, valve-in-valve TAVI has addressed this shortcoming and offers           
an alternative treatment option in patients who suffer SVD. Naturally, elderly patients            
have a shorter life expectancy than younger patients, and are thus at reduced risk of               
suffering the complications of a deteriorated bioprosthetic valve. Risk of non-SVD also            
exists in bioprosthetic valves, as in mechanical valves. However, it tends to be equally              
low to that of mechanical prostheses.  
 
A particular risk with both bioprosthetic and mechanical valves is the risk of             
prosthetic valve endocarditis. Although the prevalence of endocarditis is similar among           
both valve types, it can be a devastating complication often requiring prolonged use of              
broad-spectrum antibiotics and the need for reoperation [106]. Prosthetic valve          
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endocarditis occurs in approximately 1 to 6% of all patients with valve prostheses, with              
an annual incidence of 0.3 to 1.2% [107]. 
 
1.4 Short and Long-term Survival After Aortic Valve Replacement 
 
Historically severe AS and AR were associated with a poor prognosis. With the             
onset of symptoms in severe AS the prognosis ranges from 2 to 5 years without               
intervention, as seen in Figure 1.1. Intervention with AVR on severe AS has been shown               
by numerous studies to improve survival [49-51]. As early as 1982, patients with severe              
AS were found to have significantly improved survival compared to matched patients that             
went unoperated [95]. This improved survival has also been demonstrated in patients            
with low-gradient AS and severe left ventricular dysfunction [96-98]. Importantly,          
patients undergoing AVR have reduced survival compared with an age- and           
gender-matched general population, including among younger patients [99]. 
 
The influence of valve-type on survival is less clear, particularly in the 50 to 70               
years age range. A meta-analysis of three randomized clinical trials published in 2000 by              
Kassai et al. found that the valve-type does not significantly influence long-term survival             
[52]. A subsequent systematic review of 4 randomized controlled trials published in 2018             
by Kiyose et al. reevaluated the long-term mortality outcomes after bioprosthetic and            
mechanical prostheses [53]. They too found no statistically significant difference in the            
rate of mortality after bioprosthetic and mechanical valves. The relative risk of mortality             
between bioprosthetic and mechanical SAVR was 1.07 (95% CI 0.99-1.15). They did            
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note, however, that most of the confidence intervals (CIs) favoured mechanical valves.            
The relative risk of mortality with bioprosthetic versus mechanical valves reported in this             
systematic review was 1.07 with a 95% CI of 0.99 to 1.15. A number of more recent                 
prospective studies have evaluated the long-term mortality outcomes after AVR and are            
discussed in Chapter 2. 
 
Short-term mortality outcomes are generally reported at 30 days post-operatively.          
Two recent studies reported on short-term mortality after AVR using population-based           
nationwide databases. The first of these by Dunning et al included 41,227 patients after              
AVR in Great Britain and Ireland and found an overall short-term mortality of 4.1% [54].               
Bioprosthetic valves were associated with a 4.5% short-term mortality, which was not            
significantly higher than that of mechanical valves. This short-term mortality increased to            
8.1% for patients over the age of 80 years. A study by Goldstone et al. in 2017 looked at                   
9,942 patients in a Californian state registry [55]. They reported no significant difference             
in mortality at 30 days. The rates of 30-day mortality were 2.4% (bioprosthetic) versus              
1.6% (mechanical) for patients aged 45 to 54 years, and 1.6% (bioprosthetic) versus 1.7%              
(mechanical) for patients aged 55 to 64 years. The p-values associated with these             
comparisons were 0.15, and 0.93, respectively. 
 
Based on these and other studies, the European Society of Cardiology (ESC)            
guidelines for the management of valvular heart disease published in 2017 stated that             
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there are no significant differences in survival between mechanical and bioprosthetic           
prostheses [56]. 
 
1.5 International Guidelines 
 
Both the ESC and the American Heart Association (AHA) and American College            
of Cardiology (ACC) have produced guidelines to summarize and evaluate available           
evidence with the intent to provide recommendations to healthcare professionals          
managing valvular heart disease. The most recent ESC guidelines on valvular heart            
disease were published in 2017 [56], while the latest AHA/ACC guidelines are from 2014              
with a focused update in 2017 [41, 42]. 
 
1.5.1 Indications for Intervention 
 
Both the ESC and AHA/ACC agree in their recommendations that aortic valve            
interventions should be performed in centres with both departments of cardiology and            
cardiac surgery on site and with structured collaboration between the two, including a             
Heart Team. The choice of intervention must be based on careful individual evaluation of              
technical suitability and with consideration to the risks and benefits of each modality.             
Overall, SAVR is recommended in patients at low surgical risk, while TAVI is             
recommended in patients who are not suitable for SAVR as assessed by the Heart Team.               
In patients who are at increased surgical risk, the decision between SAVR and TAVI              
should be made by the Heart Team according to the individual patient characteristics,             
with TAVI being favoured in elderly patients suitable for transfemoral access. Both            
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organizations recommend that intervention should not be performed in patients with           
severe comorbidities when the intervention is unlikely to improve quality of life or             
survival. On the other hand, SAVR is indicated in patients with severe AS if they are                
undergoing sternotomy for another purpose, and this can be considered if the patient has              
moderate AS. 
 
The ACC/AHA and ESC strongly recommend that all symptomatic patients with           
severe AS undergo early intervention due to the associated poor prognosis. The only             
exception to this being patients with severe comorbidities that otherwise carry a less than              
one year survival. The decision to intervene becomes more complicated if there is             
low-gradient AS (i.e. a mean gradient of <40 mmHg). In patients with a low-gradient,              
intervention is indicated if there is a reduced ejection fraction and pseudosevere AS is              
excluded. Similarly, intervention is indicated if CT calcium scoring confirms the           
presence of severe AS. The ESC also makes recommendations on when to intervene for              
asymptomatic patients with severe AS. Indications include when systolic left ventricular           
dysfunction is present and not due to another cause, when the patient has an abnormal               
exercise test showing symptoms or a drop in blood pressure related to AS. 
 
1.5.2 Choice of Intervention 
 
Aspects to be considered when deciding between SAVR and TAVI in patients at             
increased surgical risk are complicated and currently in flux. The latest guidelines are             
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outlined in the corresponding ESC, AHA/ACC, and Canadian Cardiovascular Society          
(CCS) guidelines [41, 42, 56, 57]. 
 
Upon the decision to proceed with SAVR, the next major decision is between             
opting for a mechanical or bioprosthetic prosthesis. Every valve prosthesis is associated            
with its own challenges. Mechanical valves are associated with higher rates of bleeding,             
while bioprosthetic valves have higher rates of reintervention as discussed in Chapter 1.3.             
Ultimately, the decision is a shared-decision between the informed patient and their Heart             
Team. 
 
A mechanical prosthesis is recommended by the ESC if the patient is at risk of               
accelerated SVD such as from hyperparathyroidism, or if they are already on long-term             
anticoagulation (Grade 2A). A mechanical aortic valve prosthesis is recommended in           
patients less than 60 years of age (Grade 2A). However, a bioprosthetic valve is              
recommended if life-long anticoagulation is contra-indicated, if there is a low likelihood            
of future redo valve surgery, and if the patient is greater than 65 years of age (Grade 2A).                  
Both valve types are considered acceptable options in the 60 to 65 years age range. These                
age ranges differ markedly from the 2017 AHA/ACC updated recommendations. They           
recommend AVR with a mechanical prosthesis in patients less than 50 years of age who               
do not have a contraindication to anticoagulation (Grade 2A). Whereas a bioprosthetic            
valve is considered reasonable in patients more than 70 years of age (Grade 2A). Both               
options are considered acceptable in patients between 50 and 70 years of age (Grade 2A).               
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Notably, the AHA/ACC made an update to their recommendations for the 50 to 70 year               
age group between 2014 and 2017. Previously, in 2014, they considered both mechanical             
and bioprosthetic valves reasonable options for patients aged 60 to 70. Their 2017             
focused update expanded this range to 50 to 70 years, reflecting increasing use of              
bioprosthetic AVR in younger patients. 
 
1.5.3 Choice of Intervention in Special Populations 
 
It is well recognized that patients who use recreational intravenous drugs are at             
increased risk of IE and may develop associated valvular complications necessitating           
intervention. The Infectious Diseases Society of America (IDSA) has published          
guidelines addressing IE in this patient population [100]. For patients with IE who             
undergo valve surgery, they recommend an individualized choice of prosthesis by the            
surgeon (Grade 2A), and recommend avoidance of surgery when possible (Grade 2A). IE             
in this patient population predominantly affects right-sided valves (i.e. tricuspid and           
pulmonary valves). There are no recommendations specifically for IE of the aortic valve.             
Notably, IE of the left-side of the heart is associated with a severe clinical presentation               
and often requires surgery with an active infection [101]. A major difficulty in this              
patient population is that they have a high recurrence rate of IE. Thus the choice of                
prosthetic valve type must take into account the usual patient factors plus the known risk               
of re-infection. Generally, intravenous drug users (IVDU) tend to be younger and would             
otherwise benefit from mechanical valve prosthesis. Rates of endocarditis recurrence tend           
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to be similar among mechanical and bioprosthetic valves as was shown in a recent large               
retrospective study [102]. These results support the IDSA guidelines recommending an           
individualized choice for prosthetic valve type in this patient population. 
 
End-stage renal disease (ESRD) is a known risk factor for the development of AS              
as discussed in Chapter 1.1. Choice of mechanical versus bioprosthetic AVR is            
complicated in patients with ESRD. In general, these patients have a poorer prognosis at              
baseline [103]. Further, ESRD is a well recognized risk factor for bleeding and an              
etiology of abnormal calcium metabolism. As a result, some surgeons prefer to implant             
bioprosthetic valves in patients with ESRD to avoid the need for lifelong anticoagulation             
[104]. While other surgeons prefer to implant mechanical valves to avoid the risk of SVD               
related to abnormal calcium metabolism [104]. A recent study from Japan that            
retrospectively evaluated outcomes after AVR in dialysis patients observed that most           
patients received mechanical valves, regardless of their age [105]. They concluded that            
assessing overall operative risk of a dialysis patient is more important than the actual              
choice of valve prosthesis. The guidelines do not specifically address this patient            
population, and there are no randomized controlled trials to guide decision making.            
Ultimately, the choice of valve prosthesis in patients with ESRD is a shared-decision             




1.6 Trends in Mechanical and Bioprosthetic Valve Use 
 
Despite the recommendations of the AHA/ACC and ESC, the use of bioprosthetic            
valves has steadily increased in recent decades in North America and Europe [54, 55, 58,               
59]. Dunning et al. noted marked increases in the annual volume of AVR and those               
receiving bioprosthetic valves increased from 65% to 78% after analyzing 41,227 AVR            
operations in Great Britain and Ireland between 2004 and 2009 [54]. Notably, there was a               
7% increase from 18% to 25% in the use of bioprosthetic AVR in patients under 55                
years. Other population-based studies have also noted increasing use of bioprosthetic           
over mechanical valves, with a trend towards increased use in younger patients.            
Goldstone et al. noted a substantial increase in the use of bioprosthetic prostheses from              
12% to 52% from 1996 to 2013 in California [55]. Other studies from the Netherlands               
and Sweden national databases also showed an increase in bioprosthetic valve use,            
including among younger patients [60, 61]. The increasing use of bioprosthetic valves in             
younger patients has been challenged [45, 54, 55]. Stuart Head notes that it is well               
recognized that SVD is accelerated in younger patients, and remarks that life expectancy             
trends are increasing worldwide - potentially exposing patients who receive bioprosthetic           
valves to unnecessary risk of reoperation [45]. 
 
The reasons for increased use of bioprosthetic valves have been discussed [62].            
Applegate et al. noted that current literature indicates that most patients who undergo             
bioprosthetic AVR do not have a reoperation [62]. They note that the average             
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life-expectancy after AVR is 12 years. Since most bioprosthetic valves are free from             
deterioration in that time frame, patients are expected to die from other etiologies before              
their valves degenerate. Ultimately, implantation of a mechanical versus bioprosthetic          
valve is a shared-decision between the patient and surgeon. Surgeons have noted that             
patients are increasingly wary of the life-long anticoagulation required with mechanical           
valves [54] and therefore opt for bioprosthetic AVR, even at younger ages. The advent of               
valve-in-valve TAVI and other novel procedures adds a new dimension to the decision of              
implanting a bioprosthetic valve in a younger patient. 
 
Another explanation for the increasing use of bioprosthetic valves is related to the             
natural history of their degeneration. SVD is rarely an acute process, whereas the             
complications associated with mechanical valves - including hemorrhage - are often an            
acute emergency with guarded prognosis. Similarly, the negative impact of mechanical           
prostheses on the livelihoods of young active patients is significant [62]. 
 
There are developments that may favour the future use of mechanical or            
bioprosthetic valves. Lifelong anticoagulation with mechanical valves is widely         
recognized as their major disadvantage. The use of non-vitamin K antagonist           
anticoagulation with mechanical valves has been explored. Most notably, the RE-ALIGN           
trial evaluated the use of dabigatran - a direct oral anticoagulant (DOAC) - compared to               
warfarin in patients with mechanical prostheses. They noted that patients receiving           
dabigatran had more thromboembolic events and bleeding as compared to warfarin [63].            
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Despite this initial setback, others have studied the opportunity to target lower INR             
targets in mechanical valves with promising results [64, 65]. Future studies may further             
shed light on the extent to which INR targets can be reduced in an effort to reduce                 
bleeding complications while also preventing thromboembolism. Home monitoring        
systems to better regulate daily INR levels are becoming more widely used, allowing for              
improved quality of life for patients who have received mechanical valves. Concurrently,            
there is interest in developing mechanical valves using materials that are less            
thrombogenic [64, 66]. The potential benefits of these modern designs is yet to be              
established. Although bioprosthetic valves have benefited from not requiring lifelong          
anticoagulation, the guidelines do recommend low-dose aspirin for the first 3 months            
after bioprosthetic SAVR, aspirin monotherapy after TAVI [57], and state that           
consideration can be made for oral anticoagulation for the first 3 months post-operatively             
(particularly if post-operative AF is documented) [56]. Recent investigators have          
analyzed the incidence of bioprosthetic valve thrombosis [67]. Two recent studies have            
demonstrated improved outcomes with lifelong warfarin [68, 69]. These studies are           
currently interpreted with caution, particularly because the Danish study [69] showed a            
reduction in the rate of bleeding associated with warfarin use - a counterintuitive             
conclusion. Historically, patients who already had an indication for anticoagulation with           
warfarin (i.e. AF, VTE) received mechanical valves. However, with the advent of            
DOAC’s this is being reconsidered and may partially explain increasing use of            
bioprosthetic valves [70]. 
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1.7 Recent Literature Assessing Long-term Mortality After AVR 
 
Five studies were critically appraised that all analyzed long-term mortality          
outcomes in patients between 50 and 70 years of age after mechanical versus             
bioprosthetic AVR. An in-depth appraisal of these publications can be found in            
Appendices A through C. A summary of these fives studies can be found in Tables 1.1                
and 1.2. Four of the five publications reported no discernable difference in long-term             
mortality outcomes between the valve types as shown in Table 1.2. While, a study from               
Sweden reported significantly less mortality with mechanical AVR in this age group.            
However, limitations in the generalizability of their findings was a consistent issue as             
discussed in the Appendices. 
Table 1.1: Summary of five studies appraised 










McClure et al. 2014 1992 - 2001 <65 1701 (722) Brigham and Women’s 
hospital, Boston 
Chiang et al. 2014 1997 - 2004 50 - 69 4253 (2002) New York State (all 
hospitals) 
Glaser et al. 2015 1997 - 2013 50 - 69 4545 (2198) Sweden (all hospitals) 
Goldstone et al. 2017 1996 - 2013 All; stratified: 
45 - 54, and 
55 - 64 
9942 (N/A) California (all 
hospitals) 




















McClure et al. 8 (18) 
years 
60% at 18 
years 
51% at 18 
years 
0.75 Choice of valve type 
does not affect survival 
in patients <65 years 
Chiang et al. 10.8 (16.9) 
years 
61% at 15 
years 
62% at 15 
years 
0.74 Either valve type 
reasonable in patients 
aged 50 to 69 years 
Glaser et al. 7.3 (17.2) 
years 
50% at 15 
years 
59% at 15 
years 
0.006 Improved survival after 
mechanical AVR in 
patients 50 to 69 years 
Goldstone et al. 5 - 8.2 (not 
defined) 
years 
69% at 15 
years 
74% at 15 
years 
0.03 Improved survival after 
mechanical AVR in 
patients 45 to 54 years 
64% at 15 
years 
68% at 15 
years 
0.60 Either valve type 
reasonable in patients 
aged 55 to 64 years 
Caulo et al. 8.1 (17) 
years 
73% at 15 
years 
76% at 15 
years 
0.159 Either valve type 
reasonable in patients 
older than 55 years 
 
 
1.8 Aortic Valve Replacement in Newfoundland and Labrador 
 
All cardiovascular surgeries in the province of Newfoundland and Labrador (NL)           
are performed at the Health Sciences Centre in St. John’s. There is limited published              
literature reflecting the epidemiology of these surgeries. 
 
Hassan et al. summarized use of valve surgery in Canada from 1994 to 2000 in a                
publication to the Canadian Journal of Cardiology in 2004 [71]. They reported on age-              
and sex-adjusted rates of valve surgery per 100,000 people. In NL the rate of SAVR was                
6.5 per 100,000 from 1994 to 2000. This was the lowest rate among all 10 provinces in                 
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Canada. More recently, in 2018, McGuire et al reported on regional differences in AVR              
in Atlantic Canada [87]. Age- and sex-adjusted rates of AVR increased in NL during              
their study period (2010 to 2014), peaking at 26.4 per 100 000 in 2014. This incidence                
rate was significantly lower than Nova Scotia (peak of 48.8/100 000) and NB (peak of               
38.6/100 000). NL was found to have the highest proportional use of mechanical valves              
in isolated SAVR (49.0%), as compared to Nova Scotia (2.5%) and New Brunswick             
(15.8%). Although the reasons for these marked differences were unclear, it is noted that              
they “​represent variations in practice that are unique to the philosophy and            
interpretation of the evidence by the clinician group practising at each institution​”. The             
authors speculate that observed differences “​suggest potentially important differences in          
access, practice patterns and/or patient characteristics​”. 
 
Similar to other regions, the decision to proceed with SAVR and the type of              
prosthetic valve to implant (e.g. bioprosthetic or mechanical) was made by the local             
cardiovascular heart team. This team consists of local cardiologists, cardiovascular          
surgeons, intensivists and corresponding allied health and meets on a weekly basis to             
review individual patient charts. After a discussion of the patient's anatomy,           
comorbidities and other aspects a joint decision is made regarding the optimal procedure             
to undertake. 
 
There is no formally published data available for the TAVI program in NL;             
however, some details of the program were available to the authors of this thesis through               
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unpublished data and discussion with individuals involved. The program started in 2016            
and performs approximately 20 procedures per year. Prior to 2016, approximately 5 to 10              
patients were transferred out-of-province for TAVI starting in 2014. The TAVI program            
in NL is likely to evolve over time and has the potential to change SAVR practices in the                  
province, particularly when considering the possibilities of valve-in-valve procedures         
with TAVI, as outlined in Chapter 1.2.5. 
 
Based on the limited literature evaluating the epidemiology of AVR in           
Newfoundland and Labrador there is evidence that cardiovascular surgery practices in           
NL do not mirror that of other regions in Canada. As a result, it is not clear whether the                   
outcomes observed in other regions necessarily apply to the intervention and population            
of NL. 
 
1.9 Study Question 
 
Considering the updated guidelines, the trend towards increased use of          
bioprosthetic valves in younger patients, and unique aspects of the patient population            
undergoing AVR in NL the following clinical question was established. 
 
In patients between 50 to 70 years of age receiving AVR in NL, are there               
differences in long-term mortality between those patients who receive mechanical          






Hypothesis: Mechanical valves result in improved mortality outcomes as         
compared to bioprosthetic valves in patients aged 50 to 70 years who undergo AVR. 
 
Null Hypothesis: There is no difference in mortality outcomes after mechanical           
versus bioprosthetic AVR in patients aged 50 to 70 years. 
 
1.9.2 Secondary Outcomes 
 
Several secondary clinical objectives will be addressed beyond the primary          
outcome of interest of long-term survival as outlined below. 
 
● Describe the population undergoing AVR in NL, including their ages,          
preoperative comorbidities, and etiology of aortic valve pathology - including          
rates of congenital bicuspid aortic valve disease 
● Perform a secondary assessment of survival differences in an age-stratified          
sub-group of patients aged 61 to 70 years 
● Describe the intraoperative and postoperative characteristics including: frequency        
of each mechanical and bioprosthetic valve type, cardiopulmonary bypass and          
cross clamp times, and postoperative complications prior to discharge from          
hospital 
● Determine the duration of follow-up and etiology of death of patients included  
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Chapter 2: Methods 
 
2.1 Sample Size Calculation 
 
The sample size calculation for survival analysis is based on a study design with a               
power of at least 85% (i.e. 𝛽 = 0.15), a significance level of 0.05 (i.e. α = 0.05), and to                    
detect a between-group HR of 1.15 for analysis of mortality at 5 years. It is assumed that                 
the proportion of patients in each treatment group will be equal (i.e. 𝞹​1 and 𝞹​2 equal 0.5).                 
These assumptions are consistent with the literature in this field [6-10]. The survival             
analysis follows the log-rank test to test the null hypothesis of no difference between              
implantation of a mechanical or bioprosthetic valve. The required number of events            
follows the equation: 
 
vents 843e =  
(z +z )α/2 β
2
π π (logHR)1 2
2 =
(1.96+1.04)2
0.5 0.5 (log1.15)* * 2
= 1  
 
The number of patients (i.e. sample size, n) required to achieve 1843 events             
follows the equation: 
 
, where   n = eventsP r{event} r{event} 1 S (T ) S (T )]P =  − [π1 1 + π2 2  
 
Assuming exponential survival times, we can calculate S​1​(T) and S​2​(T) using the            
following equation: 
 
(T ) S (T )  S1 =  2 = e−λt  
 
S​1​(T) and S​2​(T) are functions of survival time for the mechanical and            
bioprosthetic groups, respectively. These can be assumed to be equal based on the null              
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hypothesis that both interventions are equal. Note that this calculation of event            
probability ignores patients lost to follow-up. Accounting for patients lost to follow-up            
would require a higher sample size. 
 
Based on recent studies in this field, it is expected that approximately 70% of              
patients will survive at the 5-year period [6-10]. Thus, 
 
, where 0.3 is the 5-year mortality rate.(T ) .741 S  = e−0.3 = 0  
 
r{event} 1 S (T ) S (T )] 0.5 .741 0.5 .741] .259P =  − [π1 1 + π2 2 = 1 − [ * 0 +  * 0 = 0  
 
  116n = eventsP r{event} =
1843
0.259 = 7  
 
Based on the above calculations, the sample size needed to detect a HR of 1.15,               
with an alpha of 0.05 and power of 85% is 7116 patients at 5-year follow-up. Repeating                
the calculations at 15-year follow-up, assuming a survival of 60%, yields a sample size of               
5590. This sample size was not achieved in any of the studies appraised in Chapter 2, and                 
unrealistic in an exclusively NL population. Thus, it was not anticipated that there would              
be a statistically significant difference in mortality outcomes between patients who           
received mechanical versus bioprosthetic AVR. The primary intention is to determine and            
present the outcomes of patients in NL, and compare these results with those of other               
regions while providing information to assist in the planning and delivery of future             
cardiovascular practices in NL based on our patient population.  
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2.2 Study Design and Population 
 
We analyzed data from patients who underwent isolated AVR in NL between            
2006 and 2014 to evaluate long-term survival. The Health Research Ethics Board and the              
Newfoundland and Labrador Centre for Health Information (NLCHI) approved the study           
protocol in June 2018 and November 2019, respectively. Data was acquired through a             
prospectively collected database (Alberta Provincial Program for Outcome Assessment in          
Coronary Heart Disease - APPROACH) and individualized chart-reviews. 
 
Patients were included in the study if they were 50 to 70 years of age and had                 
undergone isolated AVR in NL between 2006 and 2014. Exclusion criteria included            
out-of-province residency, concomitant coronary artery bypass grafting, other valve         
replacement or repair, and thoracic aortic surgery. 
 
Unless therapeutic anticoagulation was indicated for another reason (e.g. AF,          
VTE), patients who received a bioprosthetic AVR were managed with 3 months of             
aspirin post-operatively. Some patients who had documented postoperative AF were          
anticoagulated with warfarin for 3 months. Whereas patients who received a mechanical            
valve were anticoagulated with lifelong warfarin. The target INR with warfarin was            
between 2.0 and 3.0, as per the corresponding AHA/ACC guidelines. The decision to             
implant a bioprosthetic or mechanical valve was a shared-decision between the patient            
and the Heart Team at the time of surgery. 
 
30 
2.3 Data Collection 
 
Patient characteristics, laboratory values, and in-hospital outcomes were collected         
in the prospectively-managed APPROACH database. Variables not available in the          
APPROACH database were collected retrospectively through individualized       
chart-reviews and from discharge summaries from the hospital admission associated with           
the index surgery. Cause and date of death were obtained from the APPROACH database              
which is linked to the Statistics Canada database responsible for tracking mortality            
statistics across Canada. This data was cross-checked through individualized chart          
reviews and no discrepancies on date of death were found. All charts were reviewed              
during a two-week time period in late March 2020. Complete follow-up was achieved,             




The primary outcome was all-cause mortality. This was measured in days and            
counted from the date of the index surgery until the date of death or the last documented                 
encounter with the healthcare system (such as last blood work, imaging or clinic note).              
Related secondary outcomes calculated include: perioperative mortality (≤30 days after          
surgery), and death at 1, 5 and 10 years. Further, etiology of death will be determined                
through individualized chart reviews and from death certificates if available in the chart.             
Etiology of death was divided into one of five categories: cardiovascular, malignancy,            
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bleeding, unknown causes, and other. Sudden, unexplained death was considered a           
cardiovascular related event. 
 
A number of secondary outcomes related to procedural and post-operative          
complications will be evaluated. There are several designs of mechanical and           
bioprosthetic valves and selection was made by the operating surgeon. The type of             
mechanical and bioprosthetic valve implanted will be presented. Intraoperative statistics          
including cardiopulmonary bypass and cross clamp times will be analyzed. Postoperative           
complications including deep vein thrombosis (DVT), CVA, bleeding, AF, HF, delirium,           
re-exploratory sternotomy, need for permanent pacemaker (PPM) implantation, and         
length of stay (LOS) will all be presented and compared between the mechanical and              
bioprosthetic valve cohorts. AF was defined as any occurrence of rapid AF lasting longer              
than one hour and requiring intervention with either cardioversion or additional           
medications beyond the patient's preoperative medications. CVA includes both stroke and           
TIA’s as documented in the chart. 
 
2.5 Statistical Analysis 
 
Patient baseline characteristics are presented as mean and standard deviations for           
continuous variables, while categorical variables are presented as frequencies and          
percentages. Differences between patients receiving mechanical or bioprosthetic valves         
were evaluated through the Student’s t-test for continuous variables and Pearson’s           
chi-squared test for categorical variables. 
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To adjust for confounding variables between groups in terms of baseline           
preoperative characteristics, propensity score matching was performed. A logistic         
regression was applied to all baseline characteristics in Table 3.1 to create a propensity              
score model. The primary outcome of interest was all-cause mortality. The predictive            
model produced by the logistic regression was robust, with an area under the receiver              
operator characteristic curve of 0.836. A nearest neighbour matching algorithm, without           
replacement, was performed with a ratio of 1:1 using a maximum calibration of 0.2              
(standard deviation) of the logistic regression-based propensity scores. The mechanical          
valve cohort was the reference intervention in all analyses. Analyses were performed on             
the entire group and the propensity score matched group. Age-stratification was also            
carried out to further analyze and determine survival outcomes of patients aged 61 to 70               
years. 
 
The crude incidence of mortality at 10 years was calculated with 95% CIs.             
Cumulative survival was calculated and displayed using the Kaplan-Meier method. These           
were computed for the actuarial, propensity score matched, and age-stratified groups. A            
Cox proportional hazards regression model was used to estimate the risk of all-cause             
mortality according to type of prosthesis. This was expressed as a HR with 95% CIs. A                
forward stepwise regression analysis was conducted for the independent variables seen in            
Table 4.1. Any variable that had a significant effect on the outcome in the cox               
proportional hazards model based on a P ≤ 0.15 was entered into the final model. The                
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final model consisted of 8 variables: age, sex, diabetes, hypertension, CVA, pulmonary            
disease, dialysis, and LVEF, and valve type. 
 
All tests were 2-tailed, and an alpha level of 0.05 was considered statistically             
significant. Data management and statistical analyses were performed using SPSS          
Statistics V26 for MacOS (IBM Corp, Armonk, NY, USA) and the R Software             
environment version 3.6.3 for MacOS (R Foundation, Vienna, Austria). 
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Chapter 3: Results 
 
3.1 Study Population 
 
A total of 1035 patients received AVR in NL between 2006 and 2014. Of these,               
528 were between the ages of 50 to 70 years. After further inclusion and exclusion               
criteria were applied, a total of 189 patients remained and were included in the study as                
shown in Figure 3.1. Of these 189 patients, 135 (71%) received mechanical valves and 54               
(29%) received bioprosthetic valves. The total number of surgeries completed per year            
ranged from 8 (2006) to 31 (2011), as seen in Figure 3.2. There was a trend towards                 
increased use of bioprosthetic valves observed throughout the study period. Patients who            
received bioprosthetic valves tended to be older as shown in Figure 3.3. The mean age of                
the cohort who received mechanical valves was 59.2 ± 5 (range 50 to 70) years and for                 
the bioprosthetic group was 65.7 ± 4 (range 50 to 70) years (P < 0.001). The mode of the                   
ages in each cohort were 62 (mechanical) and 67 (bioprosthetic). The mean and             
maximum follow-up times were 8.1 ± 3.1 and 13.8 years for both cohorts, 8.4 ± 3.2 and                 
13.8 years for the mechanical valve cohort, and 7.2 ± 2.8 and 13.2 years for the                
bioprosthetic valve cohort. 
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Figure 3.2: Number of patients who underwent isolated AVR with mechanical (red) and             
bioprosthetic (green) valves in NL from 2006 to 2014 
 
 
Figure 3.3: Ages of patients who underwent AVR with mechanical (red) and            
bioprosthetic (green) valves 
 
3.2 Patient Baseline Characteristics 
 
The baseline characteristics in the actuarial cohort are shown in Table 3.1. Other             
than the variable of age, there were no statistically significant differences in the baseline              
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characteristics between the two cohorts. After propensity score matching there were no            
statistically significant differences in age and all other baseline characteristics, as shown            
in Table 3.2. As discussed in Chapter 2, all variables listed in Table 3.1 were used in the                  
development of the logistic regression model. 
Table 3.1: Baseline characteristics in the overall cohort 
 All 
patients 
(n = 189) 
Mechanical prosthesis 
(n = 135) 
Bioprosthetic prosthesis 
(n = 54) 
p-value 
Age, years (SD) 61.0 (5.8) 59.2 (5.3) 65.7 (4.2) <0.001 
Female sex 53 (28%) 40 (30%) 13 (24%) 0.434 
Comorbidities     
     Diabetes mellitus 50 (26%) 38 (28%) 12 (22%) 0.393 
     Atrial fibrillation 5 (2%) 4 (3%) 1 (2%) 0.639 
     Hypertension 130 (69%) 91 (67%) 39 (72%) 0.515 
     Dyslipidemia 141 (75%) 101 (75%) 40 (74%) 0.917 
     History of TIA/stroke 16 (8%) 11 (8%) 5 (9%) 0.819 
     Peripheral vascular 
     disease 
9 (5%) 4 (3%) 5 (9%) 0.142 
     Pulmonary disease 42 (22%) 29 (21%) 13 (24%) 0.706 
     Coronary artery disease     
          Prior MI 11 (6%) 8 (6%) 3 (6%) 0.922 
          Prior PCI 7 (4%) 4 (3%) 3 (6%) 0.457 
     Alcoholism 3 (2%) 1 (1%) 2 (4%) 0.146 
     Liver disease 4 (2%) 3 (2%) 1 (2%) 0.869 
     Cancer 2 (1%) 0 (0%) 2 (4%) 0.159 
     On hemodialysis 3 (2%) 3 (2%) 0 (0%) 0.083 
     Perioperative creatinine, 
     umol/L (SD) 
92.9 (37.6) 92.1 (40.7) 95.0 (28.4) 0.575 
     Heart failure 26 (14%) 15 (11%) 11 (20%) 0.137 
     LVEF, % (SD) 59.8 (10.2) 60.1 (10.2) 59.0 (10.1) 0.531 




Table 3.2: Baseline characteristics after propensity score matching 
 All patients 
(n = 52) 
Mechanical prosthesis 
(n = 26) 
Bioprosthetic prosthesis 
(n = 26) 
p-value 
Age, years (SD) 63.3 (4.7) 63.0 (4.6) 63.7 (4.8) 0.642 
Female sex 13 (25%) 5 (19%) 8 (31%) 0.347 
Comorbidities     
     Diabetes mellitus 13 (25%) 7 (27%) 6 (23%) 0.755 
     Atrial fibrillation 3 (6%) 2 (8%) 1 (4%) 0.561 
     Hypertension 34 (65%) 16 (62%) 18 (69%) 0.569 
     Dyslipidemia 34 (65%) 17 (65%) 17 (65%) 1 
     History of TIA/stroke 4 (8%) 2 (8%) 2 (8%) 1 
     Peripheral vascular 
     disease 
4 (8%) 2 (8%) 2 (8%) 1 
     Pulmonary disease 7 (13%) 4 (15%) 3 (12%) 0.692 
     Coronary artery disease     
          Prior MI 5 (10%) 2 (8%) 3 (12%) 0.646 
          Prior PCI 1 (2%) 0 (0%) 1 (4%) 0.327 
     Alcoholism 1 (2%) 1 (4%) 0 (0%) 0.327 
     Liver disease 0 (0%) 0 (0%) 0 (0%) N/A 
     On hemodialysis 0 (0%) 0 (0%) 0 (0%) N/A 
     Perioperative creatinine, 
     umol/L (SD) 
95.2 (26.5) 92.4 (18.8) 98.0 (32.6) 0.455 
     Heart failure 9 (17%) 4 (15%) 5 (19%) 0.720 
     LVEF, % (SD) 59.1 (11.4) 61.1 (10.8) 57.0 (11.8) 0.204 
Infective endocarditis 1 (2%) 0 (0%) 1 (4%) 0.327 
 
As shown in Figure 3.7, of the patients who received bioprosthetic valves, the             
only mortality events occurred in patients between the ages of 61 and 70. This              
observation prompted an age-stratified sub-analysis of patients aged 61 to 70 years. Of             
the 189 patients analyzed in the actuarial group, 105 (56%) were aged 61 to 70. The                
baseline characteristics of this subset of patients are shown in Table 3.3. Patients who              
received mechanical prosthesis tended to be younger (mean, 64.4 ± 2.7 vs. 66.7 ± 2.5               
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years, P = 0.009). All other baseline characteristics were balanced between the two             
cohorts in this age-stratified sub-analysis. 
 





Table 3.3: Baseline characteristics of all patients aged 61 to 70 years 
 Patients 
Aged 61-70 
(n = 105) 
Mechanical prosthesis 
(n = 56) 
Bioprosthetic prosthesis 
(n = 49) 
p-value 
Age, years (SD) 65.5 (2.8) 64.4 (2.7) 66.7 (2.5) 0.009 
Female sex 29 (28%) 16 (29%) 13 (27%) 0.817 
Comorbidities     
     Diabetes mellitus 33 (31%) 21 (38%) 12 (24%) 0.152 
     Atrial fibrillation 5 (5%) 4 (7%) 1 (2%) 0.209 
     Hypertension 77 (73%) 39 (70%) 38 (78%) 0.362 
     Dyslipidemia 78 (74%) 40 (71%) 38 (78%) 0.476 
     History of TIA/stroke 12 (11%) 7 (13%) 5 (10%) 0.714 
     Peripheral vascular 
     disease 
9 (9%) 4 (7%) 5 (10%) 0.585 
     Pulmonary disease 23 (22%) 10 (18%) 13 (27%) 0.293 
     Coronary artery disease     
          Prior MI 8 (8%) 5 (9%) 3 (6%) 0.589 
          Prior PCI 7 (7%) 4 (7%) 3 (6%) 0.836 
     Alcoholism 2 (2%) 0 (0%) 2 (4%) 0.103 
     Liver disease 3 (3%) 2 (4%) 1 (2%) 0.637 
     Cancer 2 (2%) 0 (0%) 2 (4%) 0.159 
     On hemodialysis 3 (3%) 3 (5%) 0 (0%) 0.083 
     Perioperative creatinine, 
     umol/L (SD) 
98.7 (46.0) 102.6 (56.9) 94.3 (29.2) 0.342 
     Heart failure 24 (23%) 13 (23%) 11 (22%) 0.927 
     LVEF, % (SD) 58.2 (11.3) 57.9 (12.0) 58.5 (10.5) 0.793 
Infective endocarditis 2 (2%) 1 (2%) 1 (2%) 0.925 
 
The etiology of underlying aortic valve pathology was most commonly calcific           
aortic disease (65%), followed by congenital bicuspid aortic stenosis (20%), as shown in             
Table 3.4. Of all patients who underwent AVR, 85% had severe AS on preoperative              
echocardiogram, while 16% had severe AI. There were no statistically significant           
differences in etiology of aortic valve pathology between the mechanical and           
bioprosthetic valve cohorts. 
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Two patients in this study period had redo AVR for a previously implanted valve.              
One was a St. Jude Mechanical (SJM) valve implanted in 1992 and required debridement              
in 2005 for leaflet dysfunction resulting from pannus formation. This patient then went             
on to have redo AVR in 2009, due to further pannus growth, with a bioprosthetic AVR.                
The other patient had a bioprosthetic valve implanted in 2006 (with concomitant CABG)             
that underwent SVD. This patient had significant comorbidities including prior liver           
transplantation, immunosuppressive therapy with cyclosporine, and ESRD requiring        
intermittent hemodialysis. This patient went on to have redo AVR with a mechanical             
valve in August 2010. 
Table 3.4: Etiology of underlying aortic valve pathology 
 All patients 
(n = 189) 
Mechanical prosthesis 
(n = 135) 
Bioprosthetic prosthesis 
(n = 54) 
p-value 
Severe AS 160 (85%) 119 (88%) 41 (76%) 0.064 
Calcific 123 (65%) 86 (64%) 37 (69%) 0.529 
Congenital  38 (20%) 32 (24%) 6 (11%) 0.028 
Severe AI 30 (16%) 18 (13%) 12 (22%) 0.170 
Unknown  11 (6%) 7 (5%) 4 (7%) 0.587 
Dilated  5 (3%) 4 (3%) 1 (2%) 0.639 
Rheumatic  3 (2%) 2 (1%) 1 (2%) 0.862 
Endocarditis  5 (3%) 2 (1%) 3 (6%) 0.224 
Prolapse - Posterior  1 (1%) 1 (1%) 0 (0%) 0.319 
Prosthetic Valve 
Dysfunction 
 2 (1%) 1 (1%) 1 (2%) 0.579 
Myxomatous 
Degeneration 
 1 (1%) 0 (0%) 1 (2%) 0.322 
 
3.3 Procedural Characteristics and Post-operative Complications 
 
All patients in the mechanical and bioprosthetic valve cohorts underwent full           
sternotomy with standard cardiopulmonary bypass techniques. During the study period a           
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total of six cardiovascular surgeons performed all cases. The frequency of each            
mechanical and bioprosthetic valve design implanted is shown in Tables 3.5 and 3.6. As              
discussed in Chapter 2.2, patients who received concomitant cardiovascular surgeries,          
including CABG, were excluded from this study. Intra-operative cardiopulmonary bypass          
and cross clamp times are shown in Table 3.7. There were no statistically significant              
differences in cross clamp or cardiopulmonary bypass times when comparing the           
mechanical valve cohort versus the bioprosthetic valve cohorts. 
Table 3.5: Frequency of use of each mechanical valve type 
Mechanical Valve Type Frequency 
(n = 135) 
SJM Heart Valve 60 (44%) 
CarboMedics Mech 42 (31%) 
CarboMed TopHat-SA 17 (13%) 
SJM Masters Series 9 (7%) 
SJM Regent Valve 6 (4%) 
Björk-Shil Monostrut 1 (1%) 
 
Table 3.6: Frequency of use of each bioprosthetic valve type 
Bioprosthetic Valve Type Frequency 
(n = 54) 
CE/EL Pericardial Magna 43 (80%) 
CE/EL Peri-mount/cardial 6 (11%) 
SJM Trifecta 3 (6%) 




Table 3.7: Intraoperative cardiopulmonary bypass and cross clamp times 
 All patients 
(n = 189) 
Mechanical prosthesis 
(n = 135) 
Bioprosthetic prosthesis 
(n = 54) 
p-value 
Cardiopulmonary 
bypass time (mins) 
125.3 (31.6) 125.4 (32.0) 124.9 (31.0) 0.928 
Cross clamp time (mins) 91.0 (19.4) 91.2 (19.8) 90.5 (18.5) 0.820 
 
All patients were monitored in the CVICU immediately after surgery and then            
transferred to the cardiovascular ward and eventual discharge from hospital.          
Post-operative complications, rates of PPM implantation, and LOS after the index           
surgery are listed in Table 3.8. There were no statistically significant differences in the              
post-operative complications between the mechanical and bioprosthetic cohorts. 
Table 3.8: Postoperative complications and length of stay 
 All patients 
(n = 189) 
Mechanical prosthesis 
(n = 135) 
Bioprosthetic prosthesis 
(n = 54) 
p-value 
Post-op DVT 3 (2%) 3 (2%) 0 (0%) 0.083 
Post-op AF 53 (28%) 36 (19%) 17 (31%) 0.519 
Post-op delirium 22 (12%) 16 (8%) 6 (11%) 0.886 
Post-op PPM 7 (4%) 6 (3%) 1 (2%) 0.315 
Post-op CVA 5 (3%) 1 (1%) 4 (7%) 0.075 
Post-op bleeding 18 (10%) 15 (8%) 3 (6%) 0.184 
Post-op HF 10 (5%) 9 (5%) 1 (2%) 0.092 
Re-exploratory 
sternotomy 
6 (3%) 5 (3%) 1 (2%) 0.454 




No statistically significant difference in long-term survival was observed in the           
propensity score matched group between the mechanical and bioprosthetic valve cohorts           
(P = 0.491) at a mean follow-up of 8.1 ± 3.1 years. Figures 3.4, 3.5, and 3.6 display the                   
Kaplan-Meier survival curves for the following groups: actuarial, propensity score          
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matched, and patients aged 61 to 70 years, respectively. The HR for mortality for              
mechanical versus bioprosthetic valves in the actuarial group was 1.35 (95% CI            
0.61-3.00, P = 0.46). The HR for mortality for mechanical versus bioprosthetic valves in              
the propensity score matched group was 0.638 (95% CI 0.18-2.3, P = 0.491. The HR for                
mortality for mechanical versus bioprosthetic valves in the patients aged 61 to 70 years              
was 1.321 (95% CI 0.576-3.03, P = 0.511). There were 30 deaths in the actuarial               
mechanical group and 14 in the bioprosthetic group during a maximum follow-up of 13.8              
years. The actuarial 30-day perioperative mortality was 2% and 0% for the mechanical             
and bioprosthetic cohorts, respectively. Actuarial 10-year survival was 80% in the           
mechanical group compared to 66% in the bioprosthetic group, as shown in Table 3.9.              
Survival at various time-points in the propensity matched group is shown in Table 3.10. 
 
A total of 44 deaths were observed in this study after long-term follow-up. Of 135               
patients in the mechanical cohort, there were 30 (22%) mortality events. In the 54              
patients who received bioprosthetic valves, there were 14 (26%) mortality events. The            
age at time of index surgery, of all patients who had an observed mortality event is shown                 
in Figure 3.7. All of the mortality events observed in the bioprosthetic group occurred in               
patients who were in the 61 to 70 year age range at the time of index surgery.  
 
The etiology of deaths were similar across the two cohorts. The most common             
cause of death was cardiovascular, followed by malignancy accounting for 39% and 27%             
of all deaths observed, as shown in Table 3.11. Cardiovascular etiologies accounted for             
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47% and 21% of observed deaths in the mechanical and bioprosthetic cohorts,            
respectively. This difference may be influenced by the 16% of deaths where an etiology              
was not determined. A history of DM (P = 0.009), hypertension (P = 0.002) and               
pulmonary disease (P = 0.018) were measured comorbidities observed to have a            
statistically significant influence on the outcome of survival based on the logistic            
regression. 
 
Three patients in this study were on hemodialysis prior to SAVR. Each received a              
mechanical valve. None of these patients were included in the propensity-matched           
sub-analysis as they had no neighbours in the bioprosthetic cohort that were within the              
pre-defined calibration (0.2 SD’s) of the logistic regression-based propensity scores. All           
three patients suffered mortality during the study period. The first died at 1 year              
post-operatively due to heart failure, the second passed two days post-operatively, and the             
third passed within two years of the operation due to heart failure. 
 
Five patients received SAVR due to complications of infective endocarditis. Two           
received mechanical valves and three received bioprosthetic valves. None of these           
patients had an observed mortality event. The patients in the mechanical cohort survived             
a minimum of 9.7, and 10.0 years. While those in the bioprosthetic group survived a               
minimum of 4.9, 5.7, and 11.0 years. 
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The freedom from SVD, prosthetic-valve endocarditis and prosthetic-valve        
thrombosis requiring redo AVR or TAVI was 100% for all 189 patients included in this               
study. The two patients discussed in Chapter 3.2 who had redo AVR for a previously               
implanted AVR had observed mortality events at 8.9 and 1.1 years. 
Table 3.9: Survival at various time-points, stratified by valve type, in the actuarial group 
 Actuarial group 
Mechanical (n=135) Bioprosthetic (n=54) 
30-day 97.8% (95.3 - 100) 98.1% (94.6 - 100) 
1 year 95.6%  (92.1 - 99.1) 98.1% (94.6 - 100) 
5 years 88.9% (83.7 - 94.4) 83.2% (73.8 - 93.9) 
10 years 79.7% (72.5 - 87.6) 65.9% (51.3 - 84.7) 
 
Table 3.10: Survival at various time-points, stratified by valve type, in the propensity             
matched group 
 Propensity matched group 
Mechanical (n=26) Bioprosthetic (n=26) 
30-day 100% 100% 
1 year 96.2% (89.0 - 100) 96.2% (89.0 - 100) 
5 years 84.6% (71.8 - 99.7) 88.5% (77.0 - 100) 




Figure 3.5: Survival after AVR for all patients, stratified by mechanical (red) versus             
bioprosthetic (green) valves 
 
 
Figure 3.6: Survival after AVR for the propensity score matched patients, stratified by             





Figure 3.7: Survival after AVR for patients aged 61 to 70 years, stratified by mechanical               
(red) versus bioprosthetic (green) valves 
 
 





Table 3.11: Frequency and etiology of mortality events observed in all patients 
 All 





Cardiovascular 17 (39%) 14 (47%) 3 (21%) 
Malignancy 12 (27%) 7 (23%) 5 (36%) 
Bleeding 3 (7%) 2 (7%) 1 (7%) 
Unknown 7 (16%) 4 (13%) 3 (21%) 
Other 5 (11%) 3 (10%) 2 (14%) 
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Chapter 4: Discussion 
 
This study analyzed mortality outcomes of patients aged 50 to 70 years who             
underwent isolated mechanical or bioprosthetic AVR in NL from 2006 to 2014. In total,              
189 patients satisfied the inclusion and exclusion criteria and their outcomes were            
presented after a mean follow-up of 8.1 years. The primary finding of this study is that                
there was no statistically significant difference in long-term mortality for this group. A             
separate subgroup analysis was performed on a propensity score matched group of 52             
patients and also demonstrated no statistically significant difference in survival. A further            
subgroup analysis of all patients aged 61 to 70 years was performed and also              
demonstrated no statistically significant difference in survival.  
 
While mechanical valves tend to benefit from longer durability compared with           
bioprosthetic valves, they impose a higher risk of thromboembolic events on patients and             
thus require lifelong anticoagulation. The choice of prosthesis for individual patients is a             
shared-decision made by weighing the risks and benefits of each valve type while             
considering the patients individual comorbidities. Generally clinicians recommend that         
younger patients receive mechanical valves and older patients receive bioprosthetic          
valves. This practice is supported by the ACC/AHA and ESC guidelines. However,            
intermediate-aged patients (50 to 70 years) remain an age-group without clear guidelines,            
varying practice trends, and equivocal results across various studies [81]. Increasingly,           
surgeons have opted to implant bioprosthetic valves in this age group [54, 55, 58, 59].               
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Recent advancements in both mechanical and bioprosthetic valve designs, and expanding           
use of TAVI add complexity to this field. 
 
Despite limited literature describing the epidemiology and results after SAVR in           
NL, there is evidence that the study population of NL and the cardiovascular surgery              
practices in NL have several unique features [71, 87]. Further, a founder effect has been               
observed in NL for many Mendelian disorders, and thus there is a possibility of increased               
congenital or genetic cardiac disorders such as bicuspid aortic valve. As a result, it is not                
clear whether the outcomes observed in other regions necessarily apply to the            
intervention and population of NL. These differences and limited understanding of the            
epidemiology after SAVR in NL motivated this study. 
 
4.1 Primary Outcome of Interest 
 
Five studies with similar methodology to this study were published since 2014            
from distinct regions in Europe and North America. In a retrospective study by McClure              
et al. of 1701 matched patients, choice of valve type was found to not affect survival in                 
patients less than 65 years of age [72]. Chiang et al. reported similar results in 4253                
matched patients aged 50 to 69 years [73]. A retrospective study from California by              
Goldstone et al. performed an age-stratified analysis that showed improved survival after            
mechanical AVR in patients 45 to 54 years, but no difference in outcomes in patients               
aged 55 to 64 [55]. In Caulos et al. retrospective study of 1443 matched patients there                
was no difference in survival after a mean follow-up of 8.1 years [70]. In contrast, a                
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Swedish study demonstrated, in a retrospective fashion, overall improved survival after           
mechanical AVR in patients aged 50 to 69 years [61]. Our overall results corroborate the               
results of four of these five recent studies, as they also failed to find a statistically                
significant difference in mortality after AVR with mechanical versus bioprosthetic          
valves. The patients in this study, from NL, had similar baseline characteristics, including             
age, to all of these studies and those appraised in Chapter 2. 
 
The observed 10-year survival of 80% ± 8% and 66% ± 16% for mechanical and               
bioprosthetic valves, respectively, in the actuarial group was comparable to other studies.            
McClure et al. reported survival estimates at 10 years to be 79% ± 3% and 78% ± 3%,                  
while Glaser reported survival at 10 years to be 79% and 75%. Caulo et al. reported the                 
highest 10-year survival of all studies appraised: 86% and 82% for mechanical and             
bioprosthetic valves. The 10-year survival was not reported in the two other studies             
appraised. As shown in Figures 4.3 and 4.5, and Table 4.9 and 4.10 there is a notable                 
difference in survival at 10 years (81% versus 67%) for the mechanical and bioprosthetic              
valve cohorts. This difference was not evident earlier in the follow-up period, and did not               
persist to the end of the study period. Although differences in overall survival were not               
statistically significant, this difference at 10 years raises questions of whether there is a              
clinically significant difference in mortality at 10 years. Certainly, a 14% difference in             
mortality may be considered clinically significant; however, the interpretation of this is            
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difficult due to the very wide CI’s, and the observation that this difference disappears              
beyond the 10-year mark. 
 
When looking at the Kaplan-Meier curves in Figures 4.3 and 4.5 (actuarial and             
age-stratified groups), there is a near linear rate of death for the mechanical cohort before               
an increase in mortality after 10 years. This pattern is not apparent in the propensity               
matched sub-analysis. This suggests that some of the comorbidities limit survival in the             
mechanical cohort beyond 10 years. This influence on survival may have been captured             
by the propensity scores, potentially explaining why the same pattern in increased            
mortality beyond 10 years was not observed in the propensity matched sub-analysis. This             
raises the question of which comorbidities may have influenced mortality in the            
mechanical valve cohort beyond 10 years. In the actuarial group, there was a higher              
frequency of diabetes mellitus in the mechanical valve cohort versus that of the             
bioprosthetic valves (28% versus 22%, P = 0.393). This was the comorbidity that was              
noted to have the highest association with the mechanical cohort versus the bioprosthetic             
group. Although this difference was not statistically significant, it is interesting to note             
that diabetes was one of the few comorbidities that had a statistically significant influence              
on survival in the logistic regression model (P = 0.009). The other comorbidities found to               
have a significant influence on survival in the logistic regression model (hypertension and             
pulmonary disease) had more similar frequencies in the mechanical and bioprosthetic           
cohorts (P = 0.515, and P = 0.706, respectively). Perhaps DM, a chronic progressive              
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disease with significant macrovascular and microvascular involvement, limits the         
survival of patients who receive AVR beyond 10 years from index surgery. 
 
It is worth noting that patients with symptomatic severe AS have a poor prognosis              
without intervention [2, 86]. It is commonly estimated that there is a 50% mortality at 5                
years after symptom onset without surgical intervention [2]. Similarly, patients with           
aortic regurgitation have a poor prognosis [4]. Upon the development of symptomatic            
heart failure, patients with AR have a mortality rate of 25% per year. Considering the               
similar trajectory in the natural history of severe AS and severe AR, and the fact that                
these pathologies often co-exist, it is not surprising that the five studies appraised             
grouped patients with these pathologies together in their analyses. Further, none of the             
five studies appraised noted a difference in survival outcomes after SAVR in patients             
who had AS versus AR. Considering the limited sample size and low mortality event rate               
in this study, it is also not surprising that we did not show any difference in mortality                 
between these patient groups. Since the advent of AVR, the survival of patients with              
symptomatic AS and AR has improved. Our study reports a 5-year survival of 89%              
(mechanical cohort) and 83% (bioprosthetic cohort). The reasons for the improved           
survival after surgery compared to those who do not receive surgery are manifold.             
Primarily, the underlying aortic valve pathology has been removed whether it be            
calcification, bicuspid aortic valve or endocarditis. These conditions are inherently          
progressive in nature - AVR resets or removes this timeline of a progressive disease.              
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Additionally, AS and AR are associated with concentric and eccentric remodeling of the             
heart, respectively. The heart has the ability to reverse this remodelling after removal of              
the aortic valve pathology and implantation of a prosthetic valve with near-normal            
function and hemodynamics. Although AVR offers improved outcomes with long-term          
survival, the overall survival is still reduced from age-matched individuals with no aortic             
valve pathologies. It may be possible that intervening on aortic valve pathologies before             
they become overly symptomatic can result in improved outcomes. In a 2019 published             
randomized controlled trial, Duk-Hyun Kang et al. demonstrated that patients with           
asymptomatic severe AS who underwent aortic valve interventions had improved          
mortality outcomes when compared to usual care [8]. These results may influence the             
future delivery of AVR towards earlier intervention in asymptomatic patients in an effort             
to improve overall survival. 
 
A total of 44 deaths were observed in this study. Although the etiology of deaths               
were similar across the two cohorts it is difficult to draw any conclusions due to the small                 
event rate, and the 16% of deaths where an etiology was unknown. As expected,              
cardiovascular disease was implicated in the highest percentage of deaths. It is notable             
that malignancy resulted in 27% of all deaths observed in this study, accounting for 6.3%               
of the entire study population at a mean follow-up of 8.1 years. This percentage of deaths                
is in-keeping with the most recent studies summarized by the Canadian Cancer Society             
where they found that malignancy is the leading cause of death in Canada and is               
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responsible for 30% of all deaths [108]. However, the observed 6% incidence of             
cancer-related mortality in this study (at mean follow-up of 8.1 years) is higher than the               
expected incidence for Canadians, which is 0.2% per year [109]. NL is known to have the                
highest incidence of cancer in Canada at 551 per 100,000 [108]; however, this does not               
account for the 6% incidence of mortality seen in this group. Patients who have valvular               
heart disease and undergo AVR certainly have increased rates of comorbidities than the             
general population, such as hypertension and DM. Perhaps the comorbidities that           
contribute to the development of aortic valve disease also increase risk of malignancy.             
This would suggest that these patients should at minimum undergo age-appropriate           
cancer-screening prior to consideration for cardiovascular surgery when possible.         
Appropriate and thorough screening for malignancies would likely result in improved           
understanding of a patient’s overall survival prognosis with or without SAVR.           
Furthermore, discovery of a malignancy may influence the type of valve implanted            
depending on the risk of bleeding, thrombosis and survival of that patient and             
corresponding malignancy. A malignancy that confers a high bleeding risk may influence            
the heart team’s decision towards implanting a bioprosthetic valve as they do not require              
lifelong anticoagulation and thus may be a safer option. 
 
Bleeding as an etiology of death would be expected to be higher in the mechanical               
valve cohort as these patients are on lifelong anticoagulation, usually with warfarin.            
However, the observed frequency of bleeding as an etiology of death was 7% for both               
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cohorts in this study. This may be skewed due to the high percentage of patients who had                 
an unknown etiology of death (16%) and a reflection of the low number (44) of mortality                
events included in this study. Etiology of death was collected through individualized            
chart reviews and was often available from hospital discharge summaries and patient            
death certificates. Clinicians may have over-attributed deaths to cardiovascular or a           
patient’s malignancy rather than bleeding due to biases in clinical judgement. 
 
ESRD is associated with limited survival, and is a known risk factor for the              
development of AS. All three patients in our study who were on hemodialysis prior to               
surgery received mechanical valves. No patients on hemodialysis received bioprosthetic          
valves in NL, a reflection of local surgical practices. There was 100% mortality observed              
during the study period for these patients. Etiology of death was noted to be              
cardiovascular in nature for all hemodialysis patients, and the maximum survival was less             
than 2 years. These observations are in-keeping with the known increased risk of             
mortality for patients with ESRD who receive SAVR; however a 100% mortality at two              
years is notable. 
 
4.2 Secondary Outcomes and Other Observations 
 
The statistically significantly higher frequency of patients with congenital aortic          
valve disease in the mechanical cohort (24% versus 11%, P = 0.028) is likely a reflection                
of the younger age of these patients. Bicuspid aortic valves are the most common              
congenital cardiac pathology in humans and increase the individual's risk for calcification            
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of the aortic valve and thus AS [1]. These patients tend to develop signs of severe AS a                  
decade earlier than patients with trileaflet aortic valves [1]. Since they tend to present at               
younger ages, they are more likely to receive mechanical valves. Although there were no              
other statistically significant differences in the underlying etiology of aortic valve           
pathology between the two cohorts, there was a lower frequency of patients with severe              
AI in the mechanical cohort versus the bioprosthetic cohort (13% versus 22%, P = 0.170).               
Importantly, the presence of AI did not have a significant influence on the outcome of               
death (P = 0.796). In terms of therapeutic interventions, patients with severe AS are              
generally limited to the options of SAVR or TAVI. However, patients with severe AI              
have the added options of aortic valve sparing procedures (e.g. aortic valve repair). It is               
possible that the patients in this study who had severe AI and received SAVR were a                
subset of patients with different comorbidities and surgical risk profile, in effect            
introducing a selection bias to the primary outcome results. 
 
The post-operative complications presented in Table 4.8 were all derived from           
patient charts and discharge summaries. The rates of post-operative complications are           
likely an under-estimate of the true rates experienced by patients in this study. There              
were no statistically significant differences in post-operative complications between the          
two cohorts. There was a lower frequency of CVA’s observed in the mechanical cohort              
versus the bioprosthetic cohort (1% versus 7%, P = 0.075). Patients who received             
mechanical valves received therapeutic anticoagulation within 24 to 48 hours of the index             
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surgery to reduce the risk of thromboembolism from their new mechanical valves.            
Bioprosthetic valves do not introduce as high of a risk of thromboembolism and were not               
empirically anticoagulated post-operatively unless the patient had another indication for          
anticoagulation (e.g. AF). The observed increase in CVA rates in patients who received             
bioprosthetic valves highlights the coagulopathy associated with cardiovascular surgeries         
and proposes a potential benefit for anticoagulation in the postoperative period to reduce             
the risk of CVA for patients who receive either mechanical or bioprosthetic valves. This              
potential benefit would have to be balanced by the increased risk of bleeding introduced              
by anticoagulation. It is important to note that the increased rate of CVA in the               
bioprosthetic valve cohort may be a reflection of their older age of these patients and               
increased comorbidities and thus may not be a reflection of the natural history of              
bioprosthetic valves. 
 
A significant postoperative complication evaluated in other studies is the rate of            
SVD and need for re-operation. Although the secondary outcome of long-term SVD was             
not available in the databases accessed by this study, there were no patients who had an                
index AVR between 2006 and 2014 in NL who went on to have reoperation prior to                
March 2020. All five studies appraised in Chapter 2 reported significantly higher rates of              
reoperation in the bioprosthetic valve versus mechanical valve cohorts. Their rates of            
reoperation for the bioprosthetic cohorts were: 19% at 18 years (McClure et al.), 12.1% at               
15 years (Chiang et al.), 5.2% at 17.2 years (Glaser et al.), 6.6% at 15 years (Caulo et al.)                   
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and 17.2% at 15 years (Goldstone et al.) It is unclear why patients in NL did not have any                   
observed reoperation. Perhaps the follow-up time was too short. Alternatively, patients           
who received reoperation for SVD, in the five studies discussed, tended to be younger at               
time of index surgery - this study involved only five patients who were aged 60 years or                 
younger and received bioprosthetic valves. These patients would be at highest risk of             
eventual reoperation. This may be a reflection of increased use of mechanical valves in              
younger patients in the NL practice, as reported by McGuire et al. [87].             
Echocardiography provides an opportunity to screen and monitor for the development of            
SVD post bioprosthetic valve implantation. As SVD develops, early findings could be            
detected on echocardiogram long before the need for reoperation, potentially increasing           
the sensitivity of detecting this serious and long-term complication. Although most           
patients receive regular echocardiograms this was not consistent across our patient           
population and the corresponding data was not available for this study.  
 
4.3 Differences in Study Design 
 
There are important differences in study design between our study and the five             
studies described in detail in Chapter 2. All patients in our study underwent SAVR at a                
single centre; whereas, four of the five studies drew patients from multiple centres. Other              
differences in study design are also important when interpreting and comparing the            
results of this study to others. We chose to include patients with etiologies of aortic valve                
disease including AS, AR, and IE. Caulo et al. designed their study population to be               
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exclusive to those patients who had an aortic valve dysfunction due to severe AS, while               
the studies by Chiang and Goldstone did not have access to the reason for intervention in                
their patients. As a result, we were able to include these important baseline characteristics              
in our logistic regression that produced the propensity scores. Although etiology of aortic             
valve pathology did not significantly influence the primary outcome of mortality, this            
conclusion is limited by the small numbers of patients who had AR or IE in our study. 
 
Similar to the other studies discussed, there was a trend towards increased use of              
bioprosthetic valves in NL throughout the study period. This trend towards increased use             
of bioprosthetic valves has been widely described in the literature and is thought to be the                
result of safer and more durable outcomes after bioprosthetic implantation. However, the            
overall use of SAVR peaked in the middle of our study period (31 operations in 2011)                
before declining which contrasts with the other studies discussed. It is unclear why the              
rates of SAVR in NL declined after 2011 for patients aged 50 to 70 years. The mean and                  
maximum follow-up times of 8.1 and 13.8 years for our patients was comparable to other               




This study was retrospective in nature and thus is subject to selection bias. This              
was addressed through propensity score matching based on a logistic regression analysis.            
However, these methods can only take into account known and recorded patient            
characteristics. There may be unknown or unmeasured variables that confound the           
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results, and were unable to be controlled for in the logistic regression. Since much of the                
data comes from the APPROACH administrative database it is subject to input errors and              
a number of variables were lacking (e.g. history of bleeding, medications, frailty,            
smoking status, left ventricular diameter, urgency of surgery, etc). Malignancy was found            
to be a significant cause of mortality in this patient population (27%) - known risk factors                
for malignancy were not collected by the APPROACH database or studied in this paper.              
Other studies evaluating this subject considered the performing-surgeon and number of           
AVR’s performed by each surgeon a covariate in their analysis, this data was not              
available for our patient group. Further, there may be different practices and outcomes             
associated with specific surgeons, while some surgeons may have recorded their           
postoperative complications differently on their discharge summaries. These differences         
were not captured by the databases used in this study. Although echocardiographic data             
was available through the APPROACH database and cross-checked by chart reviews, it            
may not equally reflect perioperative hemodynamics as the timing of pre-operative           
echocardiogram was variable ranging from one day to seven months prior to procedure             
date. These limitations all relate to the baseline characteristics of patients in our study.              
Missing and imprecise baseline characteristics existed in all studies reviewed by us and             
have an unknown effect on the primary outcome of mortality. 
 
As shown in Chapter 2.1, the sample size necessary to detect a HR of 1.15, with                
an alpha of 0.05 and power of 85% at 5-year follow-up would be 5590 patients. This                
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study included only 189 patients. As a result, our study was under-powered for the              
primary outcome of interest. This also led to relatively wide CIs and may have failed to                
detect true differences in outcomes after mechanical versus bioprosthetic SAVR. The           
sample size could be improved by extending the time period of the study beyond 2006 to                
2014, determining patient outcomes at a later date, or collaborating with groups in the              
Maritime provinces of Canada to combine data and outcomes. Notably, all studies            
published in the past decade that compare mortality outcomes after bioprosthetic and            
mechanical AVR have been underpowered. This may explain why the majority of these             
studies have failed to find a significant difference in outcomes. This demonstrates a need              
for meta-analyses of existing studies to integrate the results of valid studies into a clear               
signal of mortality outcomes in patients less than 60 years of age who receive mechanical               
versus bioprosthetic AVR. 
 
Unfortunately, important secondary outcomes such as bleeding, stroke, and         
readmission were not collected by the databases accessible for this study. As a result,              
analysis of long-term rates of these secondary morbidity outcomes was not possible.            
These secondary outcomes inherently influence the primary outcome of mortality. Other           
studies were able to carry out a competing risk analysis, providing a marginal probability              
for cause-specific events. These would have allowed for a more detailed understanding of             
the etiology of death of patients in our study. 
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There is a single cardiac surgery centre in NL allowing for 100% surgical and              
outcome follow-up and the long-term use of a standardized cardiac database           
(APPROACH). Despite complete follow-up of the patients involved in this study, the            
average follow-up time after index SAVR was 8 years. Longer follow-up, particularly            
beyond 10 years, has the potential to delineate differences in mortality and other             
secondary outcomes in the mechanical versus bioprosthetic cohorts. A longer follow-up           
is particularly applicable to this study population as patients who undergo bioprosthetic            
SAVR tend to suffer from SVD, and the associated complications, beyond 10 years. A              
longer follow-up period would be more likely to reflect the natural history of SVD              
observed in bioprosthetic valves. The single-centre nature of cardiovascular care in NL            
means that the decision to implant mechanical versus bioprosthetic valves is influenced            
not only by traditional considerations published in the corresponding guidelines, but also            
by local practice preferences. For example, all patients who received dialysis received            
mechanical valves in NL - this is not the case for other regions in the world. This reduces                  
generalizability of our results to other sites; however, the single-centre nature of this             
patient group increases the internal validity of the results providing an improved            




In summary, this NL study demonstrated no statistically significant differences in           
long-term survival at a mean follow-up of 8.1 years, in patients aged 50 to 70 years who                 
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underwent mechanical versus bioprosthetic AVR in NL from 2006 to 2014. The most             
common cause of death in this group was cardiovascular (39%) followed by malignancy             
(27%). These results corroborate the results of four recent studies that also failed to find a                
statistically significant difference in mortality after AVR with mechanical versus          
bioprosthetic valves. Our study, and all studies appraised were underpowered to detect a             
difference in mortality. A meta-analysis combining the results of this and other studies             
may address this limitation. 
 
The results of this study provide epidemiological insight into the prevalence of            
aortic valve disease, the utilization of AVR, and the outcomes after AVR in NL. It is                
intended that the information presented will assist in the planning and delivery of future              
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Appendix A: Methodology of Literature Review and Appraisal 
 
Search Strategy and Sources 
 
A review of the literature surrounding the question of mortality following           
mechanical versus bioprosthetic AVR began with studying the most recent guidelines           
used to direct decision making in the management of patients who are candidates for              
AVR. The most prominent of these are the 2014 AHA/ACC guidelines, the ensuing 2017              
focused update, and the 2017 ESC guidelines [41, 42, 56]. These guidelines provide a              
thorough review of current practices in the field of AVR surgery. The corresponding             
guideline-shaping publications that were cited in these guidelines, a total of 35 citations,             
provided the foundation for the initial literature review in preparation for this article. 
The PubMed, EMBASE, and Cochrane Library databases were searched initially          
in November 2017 and updated in May 2020 to find relevant literature on the topic of                
outcomes after aortic valve replacement. Key search words included the following:           
valvular heart disease, aortic stenosis, aortic regurgitation, bicuspid aortic valve,          
endocarditis, aortic valve replacement, mechanical, bioprosthetic, prostheses, cardiac        
surgery, transcatheter aortic valve replacement, ​and ​mortality and morbidity​. In total,           
2,112 citations were revealed through this search. All of the 35 citations referenced in the               
guidelines were included in this list of 2,112 citations, validating the broad search. 2,092              
articles remained after duplicates were removed. 2,031 citations were found to not be             
applicable based on their titles and abstracts leaving 61 full-text references that were             
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retrieved. Six additional references were found through review of bibliographies,          




A total of 67 articles were reviewed for inclusion and exclusion criteria. Articles             
were included for appraisal if they were relevant to the topic, published in peer reviewed               
journals, and relied on or were themselves studies that analyzed outcomes associated with             
bioprosthetic and mechanical AVR. Studies published prior to 2014 were excluded as a             
systematic review by Kiyose et al. included all studies prior to this date [53]. AVR is                
inherently an outcome-based intervention and generally randomization of patients is          
unrealistic [51], as a result randomized controlled trials are rare and was not an inclusion               
criterion. Studies were excluded if randomization or, at minimum, comparison of           
matched cohorts did not occur. Studies were considered eligible if they presented data on              
AVR in adults, and documented postoperative long-term mortality. Studies with          
inadequate follow-up (i.e. less than 5 years) were removed from the review. Additionally,             
studies that involved TAVI were excluded. Age-related data was an important criterion -             
we limited selection to studies involving adults aged 50 to 70 years of age. Only full                
publications in English were included. In cases where serial reporting of a patient cohort              
occurred only the most recent publication was included. Of the 67 articles reviewed for              




Figure: PRISMA Flowchart of search strategy for literature review and study selection            
for critical appraisal  
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Appendix B: Critical Appraisal of Five Recent Studies 
 
In total, five publications met the inclusion and exclusion criteria (see PRISMA            
FLowchart) and were appraised. These included a prospective study out of the Brigham             
and Women’s Hospital [72], a retrospective study of patients in New York State [73], a               
Swedish population-based cohort study [61], a retrospective study from California [55],           
and the ANDALVALVE study of patients in Spain [70]. These studies are briefly             
summarized in Tables 2.1 and 2.2. 
 
McClure et al. (Harvard study) [72] 
 
McClure et al. published an observational study relying on data collected both            
prospectively and retrospectively that compared long-term mortality after bioprosthetic         
and mechanical AVR in patients less than 65 years of age. The authors recognized that               
guidelines at that time removed age as an absolute indication for valve-type, and             
remarked on the paucity of data and conflicting conclusions in the literature at that time               
to support those guidelines. As a result, the authors proceeded with this study with the               
objective to determine if trends towards implanting bioprosthetic patients in younger           
patients was justifiable. They included all patients less than 65 years old who underwent              
isolated AVR at Brigham and Women’s Hospital, in Boston, Massachusetts from January            
1992 to 2011. Measured covariates that had a P-value of ≤ 0.15 in a stepwise regression                
were included in their final model. This model guided the propensity score matching             
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process and had an area under the receiver operating curve of 0.81. Long-term secondary              
outcomes were determined through voluntary mail-in questionnaires. 
The authors identified 6794 patients who underwent AVR during their study           
period, 1701 of these met the inclusion criteria of which 769 (45%) received a              
bioprosthetic valve, while 932 (55%) underwent mechanical AVR. Patients who received           
a bioprosthetic valve tended to be older, and had higher rates of hypertension and              
dyslipidemia. While patients who underwent mechanical AVR were more likely to have a             
history of stroke, endocarditis, cardiac surgery, and had a lower ejection fraction. There             
were no significant differences in the propensity matched cohorts. The authors did not             
identify a difference in the primary outcome of survival after 18 years of follow-up in the                
matched cohort. Their reported 18-year survival was 60% ± 6%, and 51% ± 14% (P =                
0.752) for the bioprosthetic versus mechanical cohorts, respectively. 
This study is limited in its generalizability due to the retrospective, single-center            
observational design. As with any retrospective study, there is always potential for            
confounding from unmeasured and unknown covariates. Several secondary outcomes         
were collected through mail-in questionnaires leading to a risk of responder bias. It is              
difficult to compare the results of this study with others as their patient population had a                
mean age of 53.5 years, and was thus several years younger than the mean age of patients                 
in two randomized controlled trials that preceded their study and the other studies             
appraised here. There was no age stratified analysis presented despite the relatively large             
patient population and wide-range of ages studied. The authors' final conclusion that            
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choice of valve prosthesis does not affect survival for any patient less than 65 years may                
not be valid as they did not perform an age-stratified analysis. They have extrapolated              
their results that came from patients that were largely between 50 to 65 years, to all                
patients less than 65 years. The authors opted to exclude patients who had any              
concomitant surgery which reduces the generalizability of their results, while maintaining           
internal validity of their results. The strengths of this study include a matched cohort that               
was the largest of its size for that date. Excellent follow-up out to 18 years post index                 
surgery that was 99% complete is remarkable considering the follow-up relied on mail-in             
questionnaires.  
 
Chiang et al. (New York State study) [73] 
 
Chiang et al. analyzed a statewide New York database to determine the            
differences in long-term survival, and secondary outcomes, after AVR. In an effort to             
improve the internal validity of their results they only included patients between the ages              
of 50 to 69. Similar to all five studies appraised here, this study was retrospective in                
design and compared outcomes in patients who received isolated AVR from January            
1997 and December 2004. Patients who underwent any concomitant cardiovascular          
surgery were excluded. Propensity score matching was carried out and was based on a              
logistic regression that utilized all measured covariates regardless of their influence on            
the primary outcome of mortality. Their model had an area under the receiver operating              
curve of 0.83. 
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A total of 10981 patients aged 50 to 69 who underwent AVR were identified. Of               
these 4253 patients satisfied their exclusion criteria, of these, 1466 (34.5%) received            
bioprosthetic valves and 2787 (65.5%) received mechanical valves. Overall mean          
follow-up was 10.8 years. Patients who received bioprosthetic valves tended to be older,             
and were more likely to have a history of diabetes mellitus (DM), cerebrovascular             
disease, liver disease, and cancer. All baseline characteristics were balanced in their            
propensity matched cohorts which included 1001 patients in each cohort. This study            
detected no difference in long-term survival and reported a 15-year survival of 60.6%             
(95% CI, 56.3%-64.9%) for the bioprosthetic group and 62.1% (95% CI, 58.2%-66.0%)            
in the mechanical group. 
The authors of this study concluded that either bioprosthetic or mechanical           
prosthesis is a reasonable choice in patients aged 60 to 69 years. Their results were based                
on an administrative database that didn’t include a number of possible confounding            
variables that have previously been shown to significantly influence the outcome of            
mortality, including frailty, etiology of aortic valve disease, and left ventricular ejection            
fraction (LVEF). A strength of this study was that it involved patients across an entire               
state which improves the generalizability of their results compared to the study by             
McClure et al. Another strength is that their study included a high number of patients all                
within the same age group and they had a relatively long follow-up period. Their results               
help delineate differences in outcomes in this age group, where practices are in flux and               
guidelines are undecided. 
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Glaser et al. (Swedish study) [61] 
 
A population-based cohort study of all patients aged 50-69 years who had            
undergone primary AVR in Sweden between 1997 and 2012 was completed by Dr.             
Glaser and colleagues at the Karolinska University Hospital, Stockholm [58]. The           
impetus for this investigation came from previous studies that challenged existing           
guidelines as they demonstrated similar long-term survival in patients aged 50-60 years            
with either mechanical or bioprosthetic AVR [6, 24]. The primary objective of this             
Swedish study was to investigate the long-term all-cause mortality in patients receiving            
mechanical and bioprosthetic AVR. This observational, nationwide, population-based,        
cohort study examined the Swedish National Patient Register and similar databases. The            
follow-up period ended on December 31, 2012. To reduce selection bias, logistic            
regression using 35 variables as covariates was used to calculate a propensity score for              
each patient. A separate analysis was performed in propensity score-matched patients           
aged 50 to 59 years and 60 to 69 years of age. Patients who had undergone prior cardiac                  
surgery or a concomitant procedure were excluded. 
A total of 4545 patients were included in the study. Of these, 2713 (60%) and               
1832 (40%) received bioprosthetic and mechanical valves, respectively. The mean          
follow-up times were 5.0 and 8.8 years in the bioprosthetic and mechanical valve cohorts,              
respectively. Complete follow-up was made possible by the comprehensive nature of the            
Swedish patient databases. Patients who received bioprosthetic valves were on average           
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63.7 years, whereas those who received a mechanical valve were on average 59.9 years.              
In the propensity score-matched cohort, all baseline characteristics were well balanced.           
The 15-year survival in the propensity score-matched cohorts were 59% in the            
mechanical valve group, and 50% in the bioprosthetic valve group. These results were             
consistent with the overall cohorts. The long-term survival was significantly greater in            
the mechanical valve than the bioprosthetic valve group. The unadjusted analysis           
demonstrated a HR HR of 1.67 (95% CI 1.44-1.94) and in the propensity score-matched              
cohort the HR was 1.34 (95% CI 1.09 - 1.66; p = 0.006). HRs for the two stratified                  
groups were 1.67 (95% CI 1.06 - 2.61; p = 0.026) for patients 50 to 59 years of age, and                    
1.08 (95% CI 0.85 - 1.36; p = 0.539) for patients 60 to 69 years of age. This study                   
demonstrated significantly higher long-term survival for patients aged 50 to 59 years who             
received mechanical AVR, as compared to those who received bioprosthetic AVR. 
The results of this study were compared to two similarly designed studies that             
found no difference in 15-year survival between the two groups [72, 73]. The quality of               
anticoagulation control in Sweden has repeatedly been shown to be exceptional [75, 76]             
and is attributed to universal access to health insurance coverage. The authors state that              
this may have favorably affected clinical outcomes among patients who received           
mechanical valves who require lifelong anticoagulation. However, they did not publish           
data on INR trends for this patient cohort. 
This study demonstrates significant improvement in survival for patients less than           
60 years of age who received mechanical AVR. However, it was an observational study              
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which has associated limitations. It is prone to input errors into the national databases that               
were used, there is a risk of selection bias among physicians who followed patients after               
AVR, and it is not possible to compare baseline characteristics that were unmeasured in              
the two cohorts. In addition, some patients may have died outside of Sweden which may               
have led to underestimation of mortality as their deaths may have not been recorded in               
the national databases. The particular strengths of this study include a large population,             
and relatively long and complete follow-up. Although their findings differ from similarly            
designed studies, the authors believe that higher quality follow-up, and specifically           
anticoagulation, explains the improved outcomes seen after mechanical AVR in Sweden.           
They highlighted the importance of close monitoring of anticoagulation in patients who            
receive mechanical valves. An age-stratified analysis may have helped delineate          
differences in outcomes in younger versus older patients in the 60 to 69 year age range.                
In summary, this study demonstrates improved mortality outcomes with mechanical AVR           
in patients less aged 50 to 69 years assuming close monitoring of anticoagulation is              
feasible. Considering that Canada also benefits from universal guaranteed healthcare, and           
has similar quality of anticoagulation [77], it is reasonable to believe that these results are               
applicable here. 
Goldstone et al. (Californian study) [55] 
 
In November of 2017 a retrospective study was published that evaluated           
outcomes in patients who underwent AVR at 142 nonfederal hospitals in California. The             
motivation for this study came from an awareness of increasing use of biologic over              
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mechanical AVR despite limited evidence to support this practice. The goal was to             
compare the long-term benefits and risks of mechanical and biologic prostheses for AVR             
in California. Data was examined from patients who underwent primary AVR at 142             
nonfederal hospitals in California between 1996 and 2013. Of note, this study did not              
exclusively analyze outcomes of individual valve designs, instead all designs were           
included. Patients who received prior cardiac surgery or had concomitant cardiac surgery            
of any kind, were excluded. Patients were stratified according to age, the categories were:              
45 to 54 years, and 55 to 64 years. Clinical follow-up was obtained through the California                
electronic medical record system and state death records. Patients who were not            
documented as having died were censored on December 31, 2013. 
Of 45,639 patients who received AVR during the study period, 9942 were eligible             
for inclusion in the study. Analysis of baseline characteristics revealed that recipients of             
biologic prostheses were older and had a higher incidence of coexisting conditions than             
recipients of mechanical AVR. Inverse probability weighting was used to balance           
baseline characteristics in each age group. The median follow-up time was 5 and 8 years               
for biologic and mechanical prosthesis, respectively. In the 45 to 54 years age group,              
long-term mortality was statistically significantly higher among recipients of a          
bioprosthetic AVR than among patients who received mechanical AVR (30.6% versus           
26.4% at 15 years; p = 0.03). The difference was not as significant for the 55 to 64 years                   
age group (36.1% versus 32.1% at 15 years; p = 0.60). These relationships were              
unaffected by multivariable adjustment or incorporation of individual hospitals as a           
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random effect. When age at time of surgery was analyzed as a continuous variable, the               
mortality benefit with mechanical AVR persisted until 53 years of age, and a HR of 1.0                
occurred at approximately 63 years of age. The final conclusion was that the benefit of               
mechanical AVR disappeared by 55 years of age. 
Similar to most studies in this field, it is a retrospective design and as such has                
inherent limitations. The study’s exclusion criteria meant that only 9942 of 45,639            
patients who underwent AVR during the study period were eligible. This relatively strict             
inclusion criteria limits the generalizability of the results. An administrative database was            
used rather than a clinical database. Therefore, it was subject to input errors and lacked               
important clinical details such as the etiology of valvular disease. A limitation of this              
study is that the median follow-up time was 5 years among patients receiving biological              
prosthesis and 8 years for those who received mechanical prosthesis. This may have             
limited the ability to discern differences in long-term outcomes for the patients in the 55               
to 64 age category. The rate of AVR involving biological prosthesis increased from             
11.5% in 1996 to 53.7% in 2013. No explanation for this trend was offered. This study                
stands out for a number of reasons: it involves a relatively high number of patients, data                
was collected from a wide variety of hospitals (142), and the study largely involves the               
use of modern prosthetic valve designs. However, the long study duration (1996 to 2013)              
introduces concern regarding changes in practice. Only patients undergoing isolated AVR           
were included in this study which improves the internal validity of the outcomes, whereas              
other studies discussed here included patients who underwent concomitant surgeries of           
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the other valves or cardiac operations. In summary, this study demonstrates improved            
mortality outcomes associated with mechanical AVR in younger patients and adds           
evidence to already existing studies that demonstrate improved outcomes with          
mechanical prosthesis in patients less than 60 years of age. 
Caulo et al. (ANDALVALVE study) [70] 
 
The most recent study appraised was published in 2019 by Rodriguez-Caulo et al.             
They performed a multicentre observational retrospective study that included all patients           
aged 50 to 65 years who received isolated AVR from 7 hospitals in Southern Spain               
between 2000 and 2015. They recognized that the decision between bioprosthetic and            
mechanical AVR remained controversial in this age group and hadn’t been studied in a              
Mediterranean population. Their primary objective was to determine long-term survival.          
They included patients with documented severe AS and excluded patients who had any             
concomitant surgery or previous cardiac surgery. Their data was sourced from a regional             
database and direct telephoning was carried out to address missing data. A 2:1 propensity              
matching was conducted to adjust for differences in baseline characteristics between the            
two groups. 
A total of 1443 patients met their inclusion and exclusion criteria, and follow-up             
was completed in 1392 (96%) of these patients. In total, 1171 (81.2%) received             
mechanical valves while 272 (18.8%) received bioprosthetic valves. The propensity          
matched cohorts included 506 patients who received mechanical valves, and 257 who            
received bioprosthetic valves. Their mean follow-up time was 8.1 years with a maximum             
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of 17 years. The use of bioprosthetic valves increased from 12% at the beginning of their                
study period to 26% towards the end. Patients who received bioprosthetic valves were on              
average older, and were more likely to have pulmonary disease, a history of stroke,              
myocardial infarction, and peripheral arterial disease. Whereas patients who received          
mechanical valves were more likely to have a history of AF. All baseline characteristics              
were balanced in the propensity matched cohorts. After propensity matching their           
reported 15-year survival was 73% and 76% (P=0.159) for the bioprosthetic and            
mechanical valve cohorts, respectively. 
The main limitation of this study is the retrospective design and thus it is subject               
to confounding from unknown and unmeasured variables. Further, Caulo et al. reported            
the highest percentage use of mechanical valves (81.2%) compared to the other studies             
appraised. To address these a 2:1 propensity matched analysis was performed. Thus twice             
as many patients who received mechanical valves were included in the final analysis. As              
a result, the patients who received bioprosthetic valves in this group had an undue              
influence on the final results. No explanation was offered to directly explain the high              
rates of mechanical AVR in Andalusia; however, the authors do point out that their              
patients tend to have smaller body surface areas and sizes [Caulo-16]. This may explain              
the increased use of mechanical valves and reduces the generalizability of their results.             
Of the five studies appraised, this was the only one that strictly included patients with               
severe AS - other studies included patients with AR, and IE. This improves the internal               
validity of their results, but may have contributed to their smaller sample size. Overall,              
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the study was under-powered to discern differences in survival between bioprosthetic and            
mechanical valves in the 50 to 65 years age group. 
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Appendix C: Key Biases and Limitations of Studies Appraised 
 
Due to the nature of the intervention being studied there are a number of potential               
sources of bias that affect all five studies appraised. Predominantly, they were all             
retrospective studies and are therefore subject to selection bias as patients were not             
randomized to intervention. In the Swiss study, 81% of patients already had a clear              
preference concerning valve choice prior to their AVR surgery as determined by a             
postoperative questionnaire [74]. To reduce selection bias all studies compared the two            
cohorts according to a list of measured baseline characteristics and generally reported            
cohorts that were similar. All studies compared the two cohorts based on their baseline              
patient characteristics for both the actuarial and propensity matched groups. The patient            
characteristics included varied across the studies depending on available data. Further, it            
is impossible to know if there are unknown characteristics that may have led to an               
influence on the results. 
Strict exclusion criteria by some studies resulted in a loss of a high proportion of               
patients identified. For example, the Californian study excluded 78% of patients. Reason            
for AVR beyond severe AS was listed as an exclusion criteria by some studies. Although               
these improve the internal validity of the results, it reduces generalizability. Certainly, the             
majority of patients undergoing AVR will have AS; however, there is a need to study the                
outcomes for patients who undergo AVR for other etiologies, particularly AR and IE. 
Data custodians and researchers who collected outcome data (i.e. mortality,          
etiology of death, stroke, etc) were likely aware of the type of prosthesis implanted. This               
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may have introduced a biased evaluation from individuals inputting these data points. For             
example, a patient with a mechanical valve who presents with vague symptoms of a CVA               
may have been more likely to be labelled as having a stroke or transient ischemic attack                
(TIA) if the observer is aware of the patient's prosthesis type and the associated increased               
risk of thromboembolism. One study used mail-in questionnaires and another used a            
telephone survey to determine their outcomes of interest. These methods rely on patients,             
and family, to recall events in the past. This method of data collection is subject to                
responder bias. 
The age groups analyzed in the appraised studies were different. This makes it             
difficult to directly compare and contrast results. Although age-stratification was carried           
out by Glaser et al. and Goldstone et al., it was not performed in the other three studies.                  
The McClure et al. study included all patients less than 65 years of age. Their youngest                
patient was less than 40 years old. Including such a wide age-range of patients reduces               
the validity of their results to the age-group of interest: 50 to 70 years. The younger                
patients in their analysis may have had an undue influence on the outcome of survival. 
Patients who receive mechanical valves require lifelong anticoagulation and thus          
regular follow-up to manage their INR with warfarin. This introduces a significant            
confounder as there is a distinction in treatment between the groups after the intervention.              
Conceivably, measurement bias may occur due to closer follow-up for patients who            
undergo mechanical AVR resulting in increased detection of complications or other           
medical issues. All 5 studies reported longer follow-up times in their mechanical cohorts,             
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potentially due to the closer follow-up of these patients. Similarly, blinding of            
intervention is impossible as the surgeon is aware of which prosthesis is being implanted,              
and the patient and physician can hear an implanted mechanical valve. This may             
introduce detection and observer biases. 
There are limitations from all studies with respect to their follow-up of patients.             
The Californian study had the lowest median follow-up time at five and eight years for               
bioprosthetic and mechanical valve cohorts, respectively. This may have limited their           
ability to discern true differences in outcomes over the long-term, particularly for patients             
in the 55 to 64 years age-range. Follow-up was limited in all studies as they relied on data                  
from their individual regions. Any patients that moved outside the regions of study will              
have been lost to follow-up. It is assumed this out-migration will have equally affected              
both the mechanical and bioprosthetic cohorts equally. 
Ultimately, none of the five studies appraised had a sample size large enough to              
detect differences in outcomes. Based on calculations carried out in similar studies [49,             
55, 73, 78-80], and in Chapter 3.1 of this paper, a sample size of over 7,000 patients is                  
needed. The largest propensity matched group involved 2,198 patients in the Glaser et al.              
study. The study by Goldstone et al. avoided the loss of patients in propensity matching               
by performing a weighted analysis of their 9942 patients. The sum of their weights was               
not presented and as such it is unclear if they were able to appropriately address this                
limitation. 
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All studies noted changes in practices in their respective regions. The rates of             
bioprosthetic valve implantation increased throughout all study periods. The reasons for           
these changes in practice are varied, but reflect evolution in valve design, experience of              
surgeons, and clinical practice. Notably, the study by Caulo et al. reported a very high               
percentage of mechanical valves, reflecting differences in practice across the regions.           
These differences limit the generalizability of the results to global modern day practices. 
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Appendix D: Ethics Application 
 
Included here is the most recent application for amendment to the Health Research Ethics              
Board (HREB) of NL. The initial application was made on 19 January 2018, and this               
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